{"content":"<li class=\"n-box-item date-title\" data-end=\"1520571599\" data-start=\"1520485200\" data-txt=\"Monday, December 23, 2019\">Thursday, March  8, 2018</li><li class=\"n-box-item sa-box-item\" data-id=\"3337878\" data-ts=\"1520566234\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WYNN\" target=\"_blank\">WYNN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337878-wynn-resorts-to-pay-2_6b-to-settle-lawsuit-japans-universal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wynn Resorts to pay $2.6B to settle lawsuit with Japan&#39;s Universal</a></h4><ul>     <li>Wynn Resorts (NASDAQ:<a href='https://seekingalpha.com/symbol/WYNN' title='Wynn Resorts, Limited'>WYNN</a>) <a href=\"https://seekingalpha.com/pr/17097623-wynn-resorts-limited-universal-entertainment-aruze-usa-reach-settlement-agreement\" target=\"_blank\">agrees to pay $2.6B</a> to settle a six-year-old lawsuit brought by Japan's Universal Entertainment Corp  and its Aruze USA unit.</li>     <li>Universal at one time held a 20% stake in Wynn but was forced by the U.S. company in 2012 to give up its shares.</li>     <li>The company has been <a href=\"https://www.marketwatch.com/story/wynn-resorts-to-pay-26-billion-to-settle-dispute-with-universal-entertainment-2018-03-08\" target=\"_blank\">under pressure to resolve the dispute</a> in the wake of the sexual harassment allegations that former Chairman and CEO Steve Wynn; as long as the litigation continued, it could have been difficult for Wynn to disentangle himself from the company as its largest shareholder.</li><li>WYNN <font color='red'>-1.7%</font> after-hours.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3337878\" data-linked=\"Wynn Resorts to pay $2.6B to settle lawsuit with Japan&#39;s Universal\" data-tweet=\"$WYNN - Wynn Resorts to pay $2.6B to settle lawsuit with Japan&#39;s Universal https://seekingalpha.com/news/3337878-wynn-resorts-to-pay-2_6b-to-settle-lawsuit-japans-universal?source=tweet\" data-url=\"https://seekingalpha.com/news/3337878-wynn-resorts-to-pay-2_6b-to-settle-lawsuit-japans-universal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337875\" data-ts=\"1520555289\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AUTO\" target=\"_blank\">AUTO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337875-autowebminus-35-on-q3-miss-ceo-cfo-exiting\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AutoWeb -35% on Q3 miss; CEO, CFO exiting</a></h4><ul>   <li>AutoWeb (NASDAQ:<a href='https://seekingalpha.com/symbol/AUTO' title='AutoWeb, Inc.'>AUTO</a>) has <font color='red'>slid 34.8%</font> after hours following a miss in its <a href=\"https://seekingalpha.com/news/3337761-autoweb-misses-0_14-misses-revenue\" target=\"_blank\">Q3 earnings</a> that also features the exit of its CEO and CFO.</li>    <li>&ldquo;The board and I have been discussing a succession plan for several months,&rdquo; says President/CEO Jeff Coats. &ldquo;After more than a decade of leading AutoWeb and 20 years on its board of directors ... I will be stepping down to begin the next phase of my life.\"</li>    <li>Kimberly Boren is exiting the chief financial officer's role April 12, he said, and Wesley Ozima will serve as interim CFO.</li>    <li>The company swung to a net loss of $65.8M from a year-ago gain of $1.4M, with this year's result including a noncash charge to income tax of $25.4M and a goodwill impairment of $37.7M.</li>    <li>Income on a non-GAAP basis fell to $0.1M from $4.7M.</li>    <li><a href=\"https://seekingalpha.com/pr/17097348-autoweb-reports-fourth-quarter-full-year-2017-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3337875\" data-linked=\"AutoWeb -35% on Q3 miss; CEO, CFO exiting\" data-tweet=\"$AUTO - AutoWeb -35% on Q3 miss; CEO, CFO exiting https://seekingalpha.com/news/3337875-autowebminus-35-on-q3-miss-ceo-cfo-exiting?source=tweet\" data-url=\"https://seekingalpha.com/news/3337875-autowebminus-35-on-q3-miss-ceo-cfo-exiting\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337871\" data-ts=\"1520552143\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNAP\" target=\"_blank\">SNAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337871-information-snap-ceos-directive-is-to-pursue-break-even-this-year\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Information: Snap CEO&#39;s directive is to pursue break-even this year</a></h4><ul>   <li>Snap (NYSE:<a href='https://seekingalpha.com/symbol/SNAP' title='Snap Inc.'>SNAP</a>) chief Evan Spiegel gave a companywide directive that the <a href=\"https://www.theinformation.com/articles/spiegel-sets-ambitious-goal-for-snap-break-even-this-year\" target=\"_blank\">goal is to work toward break-even this year</a>, The Information reports.</li>    <li>That's an aggressive timetable considering analysts don't project a profit until at least 2021, and it could mean significant cost cuts alongside a focus on increasing revenues (which would have to more than triple at current expense levels).</li>    <li>The directive came months ago but hasn't been previously reported, The Information says.</li>    <li>And if the latest layoffs weren't about cost-cutting but <a href=\"https://seekingalpha.com/news/3337694-snap-confirms-layoff-120-plus-engineering-workers-shares-minus-1_7-percent\" target=\"_blank\">restructuring engineering for efficiency</a>, then many more layoffs at the 3,000-person company could be ahead.</li>    <li>Shares <font color='red'>fell 2.1%</font> during the regular session today; they're <font color='green'>up 0.6%</font> after hours.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3337861-snap-judgment-small-firm-changing-name-clear-confusion\" target=\"_blank\">Snap judgment: Small firm changing name to clear confusion</a> (Mar. 08 2018)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3337694-snap-confirms-layoff-120-plus-engineering-workers-shares-minus-1_7-percent\" target=\"_blank\">Snap confirms layoff of 120-plus engineering workers; shares -1.7%</a> (Mar. 08 2018)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3337507-apples-high-performance-suppliers-plus-35-percent-apple-buy-snap\" target=\"_blank\">Apple's high-performance suppliers +35%; Could Apple buy Snap?</a> (Mar. 08 2018)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3337871\" data-linked=\"Information: Snap CEO&#39;s directive is to pursue break-even this year\" data-tweet=\"$SNAP - Information: Snap CEO&#39;s directive is to pursue break-even this year https://seekingalpha.com/news/3337871-information-snap-ceos-directive-is-to-pursue-break-even-this-year?source=tweet\" data-url=\"https://seekingalpha.com/news/3337871-information-snap-ceos-directive-is-to-pursue-break-even-this-year\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337870\" data-ts=\"1520551737\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ENT\" target=\"_blank\">ENT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337870-global-eagleplus-9-searchlight-invests-150m-company-names-new-ceo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Global Eagle +9% as Searchlight invests $150M, company names new CEO</a></h4><ul>   <li>Global Eagle Entertainment (NASDAQ:<a href='https://seekingalpha.com/symbol/ENT' title='Global Eagle Entertainment, Inc.'>ENT</a>) has <font color='green'>jumped 8.9%</font> after hours alongside news that it's agreed to a <a href=\"https://seekingalpha.com/pr/17097615-global-eagle-announces-150-million-investment-searchlight-capital-partners\" target=\"_blank\">$150M investment</a> from Searchlight Capital Partners, and has <a href=\"https://seekingalpha.com/pr/17097616-jeff-leddy-appointed-executive-chairman-global-eagle-entertainment\" target=\"_blank\">named a new CEO</a>.</li>    <li>CEO Jeff Leddy has been named executive chairman and chairman of the board, and Josh Marks (the company's executive VP-Connectivity) will replace him in the CEO slot, effective April 1.</li>    <li>Marks will also join the board.</li>    <li>Searchlight will invest $150M and receive that principal amount in second-lien notes due June 30, 2023. Those notes include initial payment-in-kind interest at 12%/year, that later converts to cash at 10%/year.</li>    <li>Searchlight also gets a warrant to buy about 18.1M shares for $0.01/share, not exercisable until Jan. 1, 2021, and only then if 45-day volume-weighted average price of <a href='https://seekingalpha.com/symbol/ENT' title='Global Eagle Entertainment, Inc.'>ENT</a> common stock has been at or above $4.00/share. It also gets a market warrant to buy an additional 13M shares for $1.57 each -- not exercisable until Jan. 1, 2021, if the 45-day VWAP has been at or above $2.40/share.</li>    <li>Net proceeds of the deal of about $142M will significantly strengthen liquidity, the company says; it intends to use part to repay a full $78M drawn on its revolving credit.</li>    <li>Searchlight partners Eric Zinterhofer and Eric Sondag will join the Global Eagle board.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3337870\" data-linked=\"Global Eagle +9% as Searchlight invests $150M, company names new CEO\" data-tweet=\"$ENT - Global Eagle +9% as Searchlight invests $150M, company names new CEO https://seekingalpha.com/news/3337870-global-eagleplus-9-searchlight-invests-150m-company-names-new-ceo?source=tweet\" data-url=\"https://seekingalpha.com/news/3337870-global-eagleplus-9-searchlight-invests-150m-company-names-new-ceo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:28 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337867\" data-ts=\"1520550365\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHK\" target=\"_blank\">CHK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337867-wsj-tellurian-in-talks-to-buy-louisiana-fields-from-chesapeake-energy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WSJ: Tellurian in talks to buy Louisiana fields from Chesapeake Energy</a></h4><ul>     <li>Chesapeake Energy (NYSE:<a href='https://seekingalpha.com/symbol/CHK' title='Chesapeake Energy Corporation'>CHK</a>)&nbsp;<font color='green'>+2.7%</font> after-hours following a <em>WSJ</em> report that Tellurian (NASDAQ:<a href='https://seekingalpha.com/symbol/TELL' title='Tellurian Inc.'>TELL</a>) is <a href=\"https://www.wsj.com/articles/tellurian-has-held-talks-with-chesapeake-energy-on-louisiana-fields-1520547375\" target=\"_blank\">in talks to buy</a> the company's Louisiana natural gas fields.</li>     <li>CHK&rsquo;s Louisiana fields, located in the Haynesville shale formation, are valued at ~$2B, according to Jefferies analysts.</li>     <li>TELL, which is said to be seeking to become a producer as well as exporter of natural gas, has offered CHK to take equity as a part of the asset sale, something CHK is not interested in doing, according to the report.</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3337867\" data-linked=\"WSJ: Tellurian in talks to buy Louisiana fields from Chesapeake Energy\" data-tweet=\"$CHK $CHK $TELL - WSJ: Tellurian in talks to buy Louisiana fields from Chesapeake Energy https://seekingalpha.com/news/3337867-wsj-tellurian-in-talks-to-buy-louisiana-fields-from-chesapeake-energy?source=tweet\" data-url=\"https://seekingalpha.com/news/3337867-wsj-tellurian-in-talks-to-buy-louisiana-fields-from-chesapeake-energy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>89&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337864\" data-ts=\"1520549814\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSLA\" target=\"_blank\">TSLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337864-tesla-lower-discloses-chief-accounting-officer-exit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tesla lower as it discloses chief accounting officer exit</a></h4><ul>   <li>Tesla (NASDAQ:<a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a>) Chief Accounting Officer Eric Branderiz has exited his post.</li>    <li>In a <a href=\"https://seekingalpha.com/filing/3929158\" target=\"_blank\">very brief SEC filing</a>, the company says \"On March 7, 2018, Eric Branderiz left Tesla for personal reasons. Tesla appreciates Eric's service to the company.\"</li>    <li>Perhaps spooked with low information about a key role, investors have sent Tesla shares <font color='red'>1.7% lower</font> in the postmarket session on some robust volume, though shares are off their lowest bid.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3337864\" data-linked=\"Tesla lower as it discloses chief accounting officer exit\" data-tweet=\"$TSLA - Tesla lower as it discloses chief accounting officer exit https://seekingalpha.com/news/3337864-tesla-lower-discloses-chief-accounting-officer-exit?source=tweet\" data-url=\"https://seekingalpha.com/news/3337864-tesla-lower-discloses-chief-accounting-officer-exit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>255&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337856\" data-ts=\"1520548552\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FNKO\" target=\"_blank\">FNKO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337856-after-hours-gainers-losers-3-8-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers (3/8/2018)</a></h4><ul>     <li><b>Top gainers:</b> <a href='https://seekingalpha.com/symbol/FNKO' title='Funko, Inc.'>FNKO</a> <font color='green'>+9.0%</font>. <a href='https://seekingalpha.com/symbol/ACRX' title='AcelRx Pharmaceuticals, Inc.'>ACRX</a> <font color='green'>+7.9%</font>. <a href='https://seekingalpha.com/symbol/TXMD' title='TherapeuticsMD'>TXMD</a> <font color='green'>+7.6%</font>. <a href='https://seekingalpha.com/symbol/UPLD' title='Upland Software'>UPLD</a> <font color='green'>+3.3%</font>. <a href='https://seekingalpha.com/symbol/OMED' title='OncoMed Pharmaceuticals, Inc'>OMED</a> <font color='green'>+3.2%</font>.</li><li><b>Top losers:</b> <a href='https://seekingalpha.com/symbol/FNSR' title='Finisar Corporation'>FNSR</a> <font color='red'>-8.2%</font>. <a href='https://seekingalpha.com/symbol/INSY' title='Insys Therapeutics, Inc.'>INSY</a> <font color='red'>-6.9%</font>. <a href='https://seekingalpha.com/symbol/PTX' title='Pernix Therapeutics Holdings, Inc.'>PTX</a> <font color='red'>-6.9%</font>. <a href='https://seekingalpha.com/symbol/MAT' title='Mattel, Inc.'>MAT</a> <font color='red'>-4.8%</font>. <a href='https://seekingalpha.com/symbol/GBT' title='Global Blood Therapeutics'>GBT</a> <font color='red'>-4.4%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3337856\" data-linked=\"After Hours Gainers / Losers (3/8/2018)\" data-tweet=\"$FNKO $FNKO $ACRX - After Hours Gainers / Losers (3/8/2018) https://seekingalpha.com/news/3337856-after-hours-gainers-losers-3-8-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3337856-after-hours-gainers-losers-3-8-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337838\" data-ts=\"1520546473\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HAS\" target=\"_blank\">HAS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337838-toys-r-us-planning-to-liquidate-bloomberg\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Toys &#39;R&#39; Us planning to liquidate - Bloomberg</a></h4><ul><li>Unable to find a buyer or reach a restructuring deal with creditors, Toys \"R\" Us is planning to liquidate its U.S. stores, <a href=\"https://www.bloomberg.com/news/articles/2018-03-08/toys-r-us-said-to-be-prepping-liquidation-of-u-s-operations\" target=\"_blank\">reports Bloomberg</a>.</li><li>It was only September when the operation went into Chapter 11, and obtained a $31B loan to keep stores open, but the holiday season didn't work out. Things are also quickly deteriorating in many overseas divisions.</li><li>After hours action: Hasbro (NASDAQ:<a href='https://seekingalpha.com/symbol/HAS' title='Hasbro, Inc.'>HAS</a>)<font color='red'> -2.55%</font>, Mattel (NASDAQ:<a href='https://seekingalpha.com/symbol/MAT' title='Mattel, Inc.'>MAT</a>)&nbsp;<font color='red'>-5.3</font><font color='red'>%</font>, JAKKS Pacific (NASDAQ:<a href='https://seekingalpha.com/symbol/JAKK' title='JAKKS Pacific, Inc.'>JAKK</a>) unchanged. Brick &amp; mortar competitors: Target (NYSE:<a href='https://seekingalpha.com/symbol/TGT' title='Target Corporation'>TGT</a>)&nbsp;<font color='green'>+0.6%</font>, and Walmart (NYSE:<a href='https://seekingalpha.com/symbol/WMT' title='Walmart Inc.'>WMT</a>) unchanged.</li></ul><div class=\"tiny-share-widget\" data-id=\"3337838\" data-linked=\"Toys &#39;R&#39; Us planning to liquidate - Bloomberg\" data-tweet=\"$HAS $HAS $MAT - Toys &#39;R&#39; Us planning to liquidate - Bloomberg https://seekingalpha.com/news/3337838-toys-r-us-planning-to-liquidate-bloomberg?source=tweet\" data-url=\"https://seekingalpha.com/news/3337838-toys-r-us-planning-to-liquidate-bloomberg\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>71&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337832\" data-ts=\"1520546093\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IDT\" target=\"_blank\">IDT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337832-idtminus-5_5-earnings-feature-dividend-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">IDT -5.5% as earnings feature dividend cut</a></h4><ul>   <li><a href='https://seekingalpha.com/symbol/IDT' title='IDT Corporation'>IDT</a> is <font color='red'>5.5% lower</font> after hours following the <a href=\"https://seekingalpha.com/news/3337805-idt-corporation-reports-q2-results\" target=\"_blank\">release of Q2 earnings</a> and a move to <a href=\"https://seekingalpha.com/news/3337802-idt-corporation-declares-0_09-dividend\" target=\"_blank\">cut its quarterly dividend in half</a>.</li>    <li>The company swung to a loss from operations of $0.5M from a year-ago gain of $3.1M; EBITDA fell to $6.3M from $9.3M.</li>    <li>EPS rose on a GAAP basis, to $0.06 from $0.04, but non-GAAP EPS of $0.00 fell from a year-ago $0.12.</li>    <li>The company says it now expects to spin Rafael Holdings shares out to its stockholders around March 26; that will include pharma investments and more than $100M in real estate and liquid funds.</li>    <li>\"In light of our intention to continue to invest heavily in our promising growth initiatives and the impact of the spin-off of Rafael on our balance sheet, IDT's Board of Directors has reduced our dividend for the second quarter to $0.09 per share,\" it says.</li>    <li><a href=\"https://seekingalpha.com/pr/17097462-idt-corporation-reports-second-quarter-fiscal-year-2018-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3337832\" data-linked=\"IDT -5.5% as earnings feature dividend cut\" data-tweet=\"$IDT $RFL - IDT -5.5% as earnings feature dividend cut https://seekingalpha.com/news/3337832-idtminus-5_5-earnings-feature-dividend-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3337832-idtminus-5_5-earnings-feature-dividend-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:54 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337825\" data-ts=\"1520545488\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BLFS\" target=\"_blank\">BLFS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337825-biolife-solutions-misses-0_01-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioLife Solutions misses by $0.01, beats on revenue</a></h4><ul><li>BioLife Solutions (NASDAQ:<a href='https://seekingalpha.com/symbol/BLFS' title='BioLife Solutions, Inc.'>BLFS</a>): Q4 EPS of -$0.05 <font color='red'>misses by $0.01</font>.</li><li>Revenue of $3.13M (+39.1% Y/Y) <font color='green'>beats by $0.08M</font>.</li><li>Shares <font color='green'>+2.67%</font> AH.</li><li><a href='https://seekingalpha.com/pr/17097369-biolife-solutions-announces-fourth-quarter-full-year-2017-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3337825\" data-linked=\"BioLife Solutions misses by $0.01, beats on revenue\" data-tweet=\"$BLFS - BioLife Solutions misses by $0.01, beats on revenue https://seekingalpha.com/news/3337825-biolife-solutions-misses-0_01-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3337825-biolife-solutions-misses-0_01-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337824\" data-ts=\"1520545396\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UPLD\" target=\"_blank\">UPLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337824-upland-softwareplus-4_1-on-q4-beats-upside-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Upland Software +4.1% on Q4 beats, upside guidance</a></h4><ul><li>        Upland Software (NASDAQ:<a href='https://seekingalpha.com/symbol/UPLD' title='Upland Software'>UPLD</a>) shares&nbsp;<font color='green'>gain 4.1%</font>&nbsp;aftermarket on a Q4 report that beat EPS and revenue estimates. Upside Q1 guidance has revenue from $29.6M to $30.6M (consensus: $29.17M) and in-line FY18 guidance has revenue from $120.4M to $124.4M (consensus: $122.08M).</li><li>               Key metric: Subscription and support revenue, $24.8M (+45%); adjusted EBITDA, $9.7M (+129%); cash on hand, $22.3M; operating expenses, $2.17M.&nbsp;</li><li>                  Earnings call is scheduled for 5 PM ET with a webcast available <a href=\"https://investor.uplandsoftware.com/\" target=\"_blank\">here</a>.    </li><li>               <a href=\"https://seekingalpha.com/pr/17097287-upland-software-reports-record-quarterly-full-year-2017-financial-results-44-percent-revenue\" target=\"_blank\">Press release</a>&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3337734-upland-software-beats-0_10-beats-revenue\" target=\"_blank\">Upland Software beats by $0.10, beats on revenue</a> (March 8)</li></ul><div class=\"tiny-share-widget\" data-id=\"3337824\" data-linked=\"Upland Software +4.1% on Q4 beats, upside guidance\" data-tweet=\"$UPLD - Upland Software +4.1% on Q4 beats, upside guidance https://seekingalpha.com/news/3337824-upland-softwareplus-4_1-on-q4-beats-upside-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3337824-upland-softwareplus-4_1-on-q4-beats-upside-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:43 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337819\" data-ts=\"1520545224\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TXMD\" target=\"_blank\">TXMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337819-fda-accepts-therapeuticsmds-application-for-txminus-001hr-action-date-october-28-shares-up-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA accepts TherapeuticsMD&#39;s application for TX-001HR, action date October 28; shares up 6% after hours</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/17097408-therapeuticsmd-announces-fda-acceptance-new-drug-application-nda-prescription-drug-user-fee\" target=\"_blank\">accepts for review</a> TherapeuticsMD's (NYSEMKT:<a href='https://seekingalpha.com/symbol/TXMD' title='TherapeuticsMD'>TXMD</a>) marketing application seeking approval for TX-001HR (estradiol and progesterone) for the treatment of moderate-to-severe vasomotor symptoms due to menopause. The agency's action date is October 28.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3320366-therapeuticsmd-submits-nda-txminus-001hr\" target=\"_blank\">TherapeuticsMD submits NDA for TX-001HR</a> (Dec. 28, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3337819\" data-linked=\"FDA accepts TherapeuticsMD&#39;s application for TX-001HR, action date October 28; shares up 6% after hours\" data-tweet=\"$TXMD - FDA accepts TherapeuticsMD&#39;s application for TX-001HR, action date October 28; shares up 6% after hours https://seekingalpha.com/news/3337819-fda-accepts-therapeuticsmds-application-for-txminus-001hr-action-date-october-28-shares-up-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3337819-fda-accepts-therapeuticsmds-application-for-txminus-001hr-action-date-october-28-shares-up-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337814\" data-ts=\"1520544914\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FNSR\" target=\"_blank\">FNSR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337814-finisarminus-6_4-on-q3-miss-light-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Finisar -6.4% on Q3 miss, light guidance</a></h4><ul>    <li>Finisar (NASDAQ:<a href='https://seekingalpha.com/symbol/FNSR' title='Finisar Corporation'>FNSR</a>) is <font color='red'>off 6.4%</font> in postmarket trading after its <a href=\"https://seekingalpha.com/news/3337738-finisar-misses-0_03-misses-revenue\" target=\"_blank\">fiscal Q3 earnings</a> that missed expectations and contained downside guidance for the current quarter.</li>    <li>Overall revenues declined Y/Y and grew fractionally Q/Q, despite record revenues for 100G QSFP28 transceivers and higher revenue for VCSEL arrays (offset by telecom declines and drops in other datacom transceivers).</li>    <li>Gross margin fell to 28.6% from last quarter's 30.3%.</li>    <li>Revenue by segment: Datacom products, $266M (up 3.7% Q/Q); Telecom, $66.3M (down 12.3% Q/Q).</li>    <li>For fiscal Q4 it's guiding to revenues of $300M-$320M (light of consensus for $332M), gross margin of 27-28%, operating margin of about 4% and EPS of $0.09-$0.15 (below consensus for $0.21).</li>    <li><a href=\"http://investor.finisar.com/\" target=\"_blank\">Conference call</a> to come at 5 p.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/17097316-finisar-announces-third-quarter-fiscal-2018-financial-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3337814\" data-linked=\"Finisar -6.4% on Q3 miss, light guidance\" data-tweet=\"$FNSR - Finisar -6.4% on Q3 miss, light guidance https://seekingalpha.com/news/3337814-finisarminus-6_4-on-q3-miss-light-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3337814-finisarminus-6_4-on-q3-miss-light-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>36&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337798\" data-ts=\"1520544525\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MYOK\" target=\"_blank\">MYOK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337798-myokardias-mavacamten-shows-positive-action-in-mid-stage-study-shares-up-1-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MyoKardia&#39;s mavacamten shows positive action in mid-stage study; shares up 1% after hours</a></h4><ul><li><a href=\"http://investors.myokardia.com/phoenix.zhtml?c=254211&amp;p=irol-newsArticle&amp;ID=2337154\" target=\"_blank\">Results </a>from a Phase 2 clinical trial, PIONEER-HCM, assessing MyoKardia's (NASDAQ:<a href='https://seekingalpha.com/symbol/MYOK' title='MyoKardia'>MYOK</a>) mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) showed a treatment benefit.</li><li>Patients in Cohort A&nbsp; who received once-daily doses of 10 mg, 15 mg or 20 mg of mavacamtem experienced statistically significantly improvements in heart function from baseline to week 12. Patients in Cohort 2, who received daily doses of 2mg or 5 mg, also achieved the endpoint.</li><li>The data informed the design of a Phase 3 study, EXPLORER-HCM. Dosing should commence next quarter.</li><li>Mavacamten is an orally available small molecule designed to reduce left ventricular contractility by modulating the function of cardiac myosin, the protein that drives heart muscle contraction.</li><li>Shares are up&nbsp;<font color='green'>1%</font>&nbsp;after hours. Management will host a conference call momentarily to discuss the results.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3286241-myokardia-35-percent-premarket-positive-mavacamten-results\" target=\"_blank\">MyoKardia up 35% premarket on positive mavacamten results</a> (Aug. 7, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3337798\" data-linked=\"MyoKardia&#39;s mavacamten shows positive action in mid-stage study; shares up 1% after hours\" data-tweet=\"$MYOK - MyoKardia&#39;s mavacamten shows positive action in mid-stage study; shares up 1% after hours https://seekingalpha.com/news/3337798-myokardias-mavacamten-shows-positive-action-in-mid-stage-study-shares-up-1-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3337798-myokardias-mavacamten-shows-positive-action-in-mid-stage-study-shares-up-1-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:28 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337794\" data-ts=\"1520544433\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRVL\" target=\"_blank\">MRVL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337794-marvell-technologyminus-2_8-after-q4-beats-upside-eps-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Marvell Technology -2.8% after Q4 beats, upside EPS guidance</a></h4><ul><li>        Marvell Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/MRVL' title='Marvell Technology Group, Ltd.'>MRVL</a>)&nbsp;<font color='red'>drops 2.8%</font>&nbsp;aftermarket on a Q4 report that beat EPS and revenue estimates. Q1 guidance has in-line revenue from $585M to $615M (consensus: $591.06M) and upside EPS from $0.29 to $0.33 (consensus: $0.29).</li><li>               More Q1 guidance: Non-GAAP gross margin, 62% to 63%; operating expenses, $215M.&nbsp;</li><li>               Segment revenue: Storage, $323.7M (+4% Y/Y; +3% Q/Q); Networking, $155.3M (+5%; +3%); Connectivity, $86.27M (+31%; -16%); Other, $50.1M (+20%; +5%).&nbsp;</li><li>                  Key metrics: Non-GAAP gross margin, 62.3%; cash flow from operations, $120M; cash and short-term investments, $1.8B; total liabilities, $566.87M.&nbsp;    </li><li>                  Earnings call is scheduled for 4:45 PM ET with a webcast available <a href=\"http://investor.marvell.com/phoenix.zhtml?c=120802&amp;p=irol-irhome\" target=\"_blank\">here</a>.    </li><li>               <a href=\"https://seekingalpha.com/pr/17097370-marvell-technology-group-ltd-reports-fourth-quarter-fiscal-year-2018-financial-results\" target=\"_blank\">Press release</a>&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3337751-marvell-technology-group-beats-0_01-beats-revenue\" target=\"_blank\">Marvell Technology Group beats by $0.01, beats on revenue</a> (March 8)</li></ul><div class=\"tiny-share-widget\" data-id=\"3337794\" data-linked=\"Marvell Technology -2.8% after Q4 beats, upside EPS guidance\" data-tweet=\"$MRVL - Marvell Technology -2.8% after Q4 beats, upside EPS guidance https://seekingalpha.com/news/3337794-marvell-technologyminus-2_8-after-q4-beats-upside-eps-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3337794-marvell-technologyminus-2_8-after-q4-beats-upside-eps-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:27 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337749\" data-ts=\"1520544248\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AIG\" target=\"_blank\">AIG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337749-evercore-isi-cuts-aig-earnings-outlook-lowers-price-target-to-68\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Evercore ISI cuts AIG earnings outlook, lowers price target to $68</a></h4><ul><li>Declining returns on the RMBS portfolio is the main reason Evercore ISI analyst Thomas Gallagher cut AIG's (<a href='https://seekingalpha.com/symbol/AIG' title='American International Group Inc'>AIG</a> <font color='red'>-1.8%</font>) EPS estimate going into 2019.</li><li>Investment income performed strongly last year due to favorable tightening in RMBS spreads, but that seems unlikely to repeat this year and next.</li><li>Gallagher cut AIG&rsquo;s 2018 and 2019 EPS estimates by $0.40 per share to $5.16, and $5.66 respectively.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3337749\" data-linked=\"Evercore ISI cuts AIG earnings outlook, lowers price target to $68\" data-tweet=\"$AIG - Evercore ISI cuts AIG earnings outlook, lowers price target to $68 https://seekingalpha.com/news/3337749-evercore-isi-cuts-aig-earnings-outlook-lowers-price-target-to-68?source=tweet\" data-url=\"https://seekingalpha.com/news/3337749-evercore-isi-cuts-aig-earnings-outlook-lowers-price-target-to-68\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337787\" data-ts=\"1520544063\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FNKO\" target=\"_blank\">FNKO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337787-funko-beats-0_07-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Funko beats by $0.07, beats on revenue</a></h4><ul><li>Funko (NASDAQ:<a href='https://seekingalpha.com/symbol/FNKO' title='Funko, Inc.'>FNKO</a>): Q4 EPS of $0.22 <font color='green'>beats by $0.07</font>.</li><li>Revenue of $169.47M (+28.0% Y/Y) <font color='green'>beats by $22.89M</font>.</li><li>Shares <font color='green'>+1.76%</font> AH.</li><li><a href='https://seekingalpha.com/pr/17097390-funko-reports-fourth-quarter-fiscal-2017-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3337787\" data-linked=\"Funko beats by $0.07, beats on revenue\" data-tweet=\"$FNKO - Funko beats by $0.07, beats on revenue https://seekingalpha.com/news/3337787-funko-beats-0_07-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3337787-funko-beats-0_07-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337778\" data-ts=\"1520543854\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KMG\" target=\"_blank\">KMG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337778-kmg-chemicals-beats-0_32-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KMG Chemicals beats by $0.32, beats on revenue</a></h4><ul><li>KMG Chemicals (NYSE:<a href='https://seekingalpha.com/symbol/KMG' title='KMG Chemicals, Inc.'>KMG</a>): Q2 EPS of $1.04 <font color='green'>beats by $0.32</font>.</li><li>Revenue of $113.85M (+44.0% Y/Y) <font color='green'>beats by $1.28M</font>.</li><li>Shares <font color='green'>+3.1%</font> AH.</li><li><a href='https://seekingalpha.com/pr/17097416-kmg-reports-second-quarter-2018-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3337778\" data-linked=\"KMG Chemicals beats by $0.32, beats on revenue\" data-tweet=\"$KMG - KMG Chemicals beats by $0.32, beats on revenue https://seekingalpha.com/news/3337778-kmg-chemicals-beats-0_32-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3337778-kmg-chemicals-beats-0_32-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:17 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337770\" data-ts=\"1520543614\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNMX\" target=\"_blank\">SNMX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337770-senomyx-beats-0_21-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Senomyx beats by $0.21, beats on revenue</a></h4><ul><li>Senomyx (NASDAQ:<a href='https://seekingalpha.com/symbol/SNMX' title='Senomyx, Inc.'>SNMX</a>): Q4 EPS of $0.15 <font color='green'>beats by $0.21</font>.</li><li>Revenue of $14.93M (+255.5% Y/Y) <font color='green'>beats by $10.1M</font>.</li><li>Shares <font color='green'>+31.36%</font> AH.</li><li><a href='https://seekingalpha.com/pr/17097340-senomyx-reports-fourth-quarter-fiscal-year-2017-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3337770\" data-linked=\"Senomyx beats by $0.21, beats on revenue\" data-tweet=\"$SNMX - Senomyx beats by $0.21, beats on revenue https://seekingalpha.com/news/3337770-senomyx-beats-0_21-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3337770-senomyx-beats-0_21-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:13 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337757\" data-ts=\"1520543360\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UNFI\" target=\"_blank\">UNFI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337757-united-natural-foods-beats-0_16-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">United Natural Foods beats by $0.16, beats on revenue</a></h4><ul><li>United Natural Foods (NYSE:<a href='https://seekingalpha.com/symbol/UNFI' title='United Natural Foods, Inc.'>UNFI</a>): Q2 EPS of $0.71 <font color='green'>beats by $0.16</font>.</li><li>Revenue of $2.53B (+10.5% Y/Y) <font color='green'>beats by $80M</font>.</li><li>Shares <font color='green'>+3.57%</font> AH.</li><li><a href='https://seekingalpha.com/pr/17097363-united-natural-foods-inc-announces-second-quarter-fiscal-2018-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3337757\" data-linked=\"United Natural Foods beats by $0.16, beats on revenue\" data-tweet=\"$UNFI - United Natural Foods beats by $0.16, beats on revenue https://seekingalpha.com/news/3337757-united-natural-foods-beats-0_16-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3337757-united-natural-foods-beats-0_16-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337750\" data-ts=\"1520543236\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACRX\" target=\"_blank\">ACRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337750-acelrx-pharmaceuticals-eps-in-line-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AcelRx Pharmaceuticals EPS in-line, misses on revenue</a></h4><ul><li>AcelRx Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ACRX' title='AcelRx Pharmaceuticals, Inc.'>ACRX</a>): Q4 EPS of -$0.20 in-line.</li><li>Revenue of $0.74M (-88.5% Y/Y) <font color='red'>misses by $4.51M</font>.</li><li>Shares <font color='green'>+5.28%</font> AH.</li><li><a href='https://seekingalpha.com/pr/17097380-acelrx-pharmaceuticals-reports-fourth-quarter-2017-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3337750\" data-linked=\"AcelRx Pharmaceuticals EPS in-line, misses on revenue\" data-tweet=\"$ACRX - AcelRx Pharmaceuticals EPS in-line, misses on revenue https://seekingalpha.com/news/3337750-acelrx-pharmaceuticals-eps-in-line-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3337750-acelrx-pharmaceuticals-eps-in-line-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:07 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337748\" data-ts=\"1520543198\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LOCO\" target=\"_blank\">LOCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337748-el-pollo-loco-beats-0_01-revenue-in-line\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">El Pollo Loco beats by $0.01,  revenue in-line</a></h4><ul><li>El Pollo Loco (NASDAQ:<a href='https://seekingalpha.com/symbol/LOCO' title='El Pollo Loco Holdings'>LOCO</a>): Q4 EPS of $0.11 <font color='green'>beats by $0.01</font>.</li><li>Revenue of $95.2M (+2.9% Y/Y) in-line.</li><li>Shares <font color='green'>+1.04%</font> AH.</li><li><a href='https://seekingalpha.com/pr/17097354-el-pollo-loco-holdings-inc-announces-fourth-quarter-2017-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3337748\" data-linked=\"El Pollo Loco beats by $0.01,  revenue in-line\" data-tweet=\"$LOCO - El Pollo Loco beats by $0.01, revenue in-line https://seekingalpha.com/news/3337748-el-pollo-loco-beats-0_01-revenue-in-line?source=tweet\" data-url=\"https://seekingalpha.com/news/3337748-el-pollo-loco-beats-0_01-revenue-in-line\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337746\" data-ts=\"1520543180\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GBT\" target=\"_blank\">GBT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337746-global-blood-launches-3_5m-share-stock-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Global Blood launches 3.5M-share stock offering</a></h4><ul><li>Global Blood Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/GBT' title='Global Blood Therapeutics'>GBT</a>) <a href=\"https://seekingalpha.com/pr/17097305-global-blood-therapeutics-announces-proposed-public-offering-common-stock\" target=\"_blank\">commences </a>a public offering of 3.5M shares of common stock. Underwriters over-allotment is an additional 525K shares. Price and terms have yet to be released.</li></ul><div class=\"tiny-share-widget\" data-id=\"3337746\" data-linked=\"Global Blood launches 3.5M-share stock offering\" data-tweet=\"$GBT - Global Blood launches 3.5M-share stock offering https://seekingalpha.com/news/3337746-global-blood-launches-3_5m-share-stock-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3337746-global-blood-launches-3_5m-share-stock-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337742\" data-ts=\"1520543107\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LMNR\" target=\"_blank\">LMNR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337742-limoneira-beats-0_04-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Limoneira beats by $0.04, beats on revenue</a></h4><ul><li>Limoneira (NASDAQ:<a href='https://seekingalpha.com/symbol/LMNR' title='Limoneira'>LMNR</a>): Q1 EPS of -$0.09 <font color='green'>beats by $0.04</font>.</li><li>Revenue of $31.59M (+12.5% Y/Y) <font color='green'>beats by $2.82M</font>.</li><li>Shares <font color='green'>+1.64%</font> AH.</li><li><a href='https://seekingalpha.com/pr/17097320-limoneira-company-announces-first-quarter-fiscal-year-2018-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3337742\" data-linked=\"Limoneira beats by $0.04, beats on revenue\" data-tweet=\"$LMNR - Limoneira beats by $0.04, beats on revenue https://seekingalpha.com/news/3337742-limoneira-beats-0_04-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3337742-limoneira-beats-0_04-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:05 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337740\" data-ts=\"1520543073\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PDLI\" target=\"_blank\">PDLI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337740-pdl-biopharma-beats-0_12-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PDL BioPharma beats by $0.12, beats on revenue</a></h4><ul><li>PDL BioPharma (NASDAQ:<a href='https://seekingalpha.com/symbol/PDLI' title='PDL BioPharma, Inc.'>PDLI</a>): Q4 EPS of $0.15 <font color='green'>beats by $0.12</font>.</li><li>Revenue of $68M (+2.3% Y/Y) <font color='green'>beats by $22.7M</font>.</li><li>Shares <font color='green'>+3.8%</font> AH.</li><li><a href='https://seekingalpha.com/pr/17097323-pdl-biopharma-announces-fourth-quarter-year-end-2017-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3337740\" data-linked=\"PDL BioPharma beats by $0.12, beats on revenue\" data-tweet=\"$PDLI - PDL BioPharma beats by $0.12, beats on revenue https://seekingalpha.com/news/3337740-pdl-biopharma-beats-0_12-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3337740-pdl-biopharma-beats-0_12-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337739\" data-ts=\"1520543052\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VNRX\" target=\"_blank\">VNRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337739-volitionrx-readies-stock-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">VolitionRx readies stock offering</a></h4><ul><li>VolitionRx (NYSEMKT:<a href='https://seekingalpha.com/symbol/VNRX' title='VolitionRX Ltd'>VNRX</a>) <a href=\"https://seekingalpha.com/pr/17097318-volitionrx-announces-proposed-underwritten-public-offering-common-stock\" target=\"_blank\">initiates </a>a public offering of common stock. Price, volume and terms have yet to be announced.</li><li><strong>Update</strong>: Shares are down&nbsp;<font color='red'>20%</font>&nbsp;premarket on Friday, March 9, on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3337739\" data-linked=\"VolitionRx readies stock offering\" data-tweet=\"$VNRX - VolitionRx readies stock offering https://seekingalpha.com/news/3337739-volitionrx-readies-stock-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3337739-volitionrx-readies-stock-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337729\" data-ts=\"1520542501\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RGLS\" target=\"_blank\">RGLS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337729-regulus-down-30-on-extended-timeline-for-mid-stage-study-of-rgminus-012\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Regulus down 30% on extended timeline for mid-stage study of RG-012</a></h4><ul><li>Nano cap Regulus Therapeutics (<a href='https://seekingalpha.com/symbol/RGLS' title='Regulus Therapeutics'>RGLS</a> <font color='red'>-29.6%</font>) is down on more than an 8x surge in volume in apparent reaction to its <a href=\"https://seekingalpha.com/pr/17095793-regulus-reports-fourth-quarter-year-end-2017-financial-results-pipeline-update\" target=\"_blank\">disclosure </a>that enrollment in the Phase 2 clinical trial, HERA, assessing RG-012 in patients with Alport syndrome and the related renal biopsy studies should be completed in H2. Top-line results were projected for Q4 but now will extend into 2019.</li></ul><div class=\"tiny-share-widget\" data-id=\"3337729\" data-linked=\"Regulus down 30% on extended timeline for mid-stage study of RG-012\" data-tweet=\"$RGLS - Regulus down 30% on extended timeline for mid-stage study of RG-012 https://seekingalpha.com/news/3337729-regulus-down-30-on-extended-timeline-for-mid-stage-study-of-rgminus-012?source=tweet\" data-url=\"https://seekingalpha.com/news/3337729-regulus-down-30-on-extended-timeline-for-mid-stage-study-of-rgminus-012\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:55 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337726\" data-ts=\"1520541608\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PFE\" target=\"_blank\">PFE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337726-fda-ad-com-back-pfizers-xeljanz-for-certain-uc-patients-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA Ad Com back Pfizer&#39;s Xeljanz for certain UC patients; shares up 2%</a></h4><ul><li>The FDA's Gastrointestinal Drugs Advisory Committee voted 15 - 0 in favor of including a higher dosing regimen (10 mg twice daily) for Pfizer's (<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a> <font color='green'>+1.5%</font>) XELJANZ (tofacitinib) for adult patients with moderately to severely active ulcerative colitis &#40;UC&#41;&nbsp;who have not responded adequately to corticosteroids, azathioprine, 6-mercaptopurine or tumor necrosis factor inhibitor therapy. Physicians will have the option of administering 5 mg or 10 mg twice daily for these patients.</li><li>The vote was split on the question of the need for a post-marketing efficacy study, 7 in favor and 8 opposed.</li><li>The FDA's action date is in June.</li></ul><div class=\"tiny-share-widget\" data-id=\"3337726\" data-linked=\"FDA Ad Com back Pfizer&#39;s Xeljanz for certain UC patients; shares up 2%\" data-tweet=\"$PFE - FDA Ad Com back Pfizer&#39;s Xeljanz for certain UC patients; shares up 2% https://seekingalpha.com/news/3337726-fda-ad-com-back-pfizers-xeljanz-for-certain-uc-patients-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3337726-fda-ad-com-back-pfizers-xeljanz-for-certain-uc-patients-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:40 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337722\" data-ts=\"1520540550\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UTHR\" target=\"_blank\">UTHR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337722-united-therapeutics-tries-to-reverse-downtrend-up-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">United Therapeutics tries to reverse downtrend, up 6%</a></h4><ul><li>United Therapeutics (<a href='https://seekingalpha.com/symbol/UTHR' title='United Therapeutics Corporation'>UTHR</a> <font color='green'>+5.6%</font>) is up average volume in an attempt to break free of the persistent downtrend. Shares had lost&nbsp;<font color='red'>27%</font>&nbsp;of their value this year before today's action.</li><li>Wedbush's Liana Moussatos (BUY/$234) says investors have been \"short-sighted,\" not appreciating the company's growth potential. She expects Orenitram sales to continue accelerating which will offset the generic encroachment on top sellers Remodulin and Adcirca.</li><li>Goldman is not as bullish, having trimmed its price target to $98 (16% downside risk) from $111 last week. It sees a deceleration in top-line growth due to competitive headwinds and generic competition for the two top sellers mentioned.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3337722\" data-linked=\"United Therapeutics tries to reverse downtrend, up 6%\" data-tweet=\"$UTHR - United Therapeutics tries to reverse downtrend, up 6% https://seekingalpha.com/news/3337722-united-therapeutics-tries-to-reverse-downtrend-up-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3337722-united-therapeutics-tries-to-reverse-downtrend-up-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337720\" data-ts=\"1520540314\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CF\" target=\"_blank\">CF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337720-cf-industries-slides-on-double-downgrade-from-bofa-merrill\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CF Industries slides on double downgrade from BofA Merrill</a></h4><ul>     <li>CF Industries (<a href='https://seekingalpha.com/symbol/CF' title='CF Industries Holdings, Inc.'>CF</a> <font color='red'>-2.5%</font>) is lower after BofA&nbsp;Merrill Lynch slams shares with a <a href=\"https://thefly.com/thestreet/realmoney/index.php/CFid2696012/CF-CF-Industries-downgraded-to-Underperform-from-Buy-at-BofAMerrill\" target=\"_blank\">two-notch downgrade</a> to Underperform from Buy with a $40 price target, cut from $48, amid a cautious view on nitrogen fertilizer demand as China increases fertilizer formulations which could result in multi-year demand declines.</li>     <li>BAML sees risk to nitrogen pricing in H2 2018 due to increasing Chinese production rates, ending seasonal demand in the Northern Hemisphere, a positive net export position in the U.S. in the summer-fill season, and lower international energy prices following seasonality.</li>     <li>The firm also believes CF can achieve ~$5/share in free cash flow but not until 2020 or later, vs. its previous forecast of 2019 or later.</li></ul><div class=\"tiny-share-widget\" data-id=\"3337720\" data-linked=\"CF Industries slides on double downgrade from BofA Merrill\" data-tweet=\"$CF - CF Industries slides on double downgrade from BofA Merrill https://seekingalpha.com/news/3337720-cf-industries-slides-on-double-downgrade-from-bofa-merrill?source=tweet\" data-url=\"https://seekingalpha.com/news/3337720-cf-industries-slides-on-double-downgrade-from-bofa-merrill\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337718\" data-ts=\"1520539444\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FTD\" target=\"_blank\">FTD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337718-ftd-dives-after-warning-wont-meet-financial-covenant-terms\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FTD dives after warning it won&#39;t meet financial covenant terms</a></h4><ul>     <li>FTD Companies (<a href='https://seekingalpha.com/symbol/FTD' title='FTD Companies, Inc.'>FTD</a> <font color='red'>-35.1%</font>) craters&nbsp;after the company warns that it won't be able to comply with certain financial covenants in its credit agreement.</li>     <li>The company says it's in discussion with lenders and large shareholder Liberty Interactive regarding credit agreement modifications and other financing transactions.</li><li>FTD also <a href=\"https://seekingalpha.com/pr/17096002-ftd-companies-inc-announces-preliminary-unaudited-full-year-2017-results\" target=\"_blank\">issued</a> preliminary 2017 results and updated 2018 guidance, including the expectation for Q1 revenue to fall short of prior expectations by $20M.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3337718\" data-linked=\"FTD dives after warning it won&#39;t meet financial covenant terms\" data-tweet=\"$FTD - FTD dives after warning it won&#39;t meet financial covenant terms https://seekingalpha.com/news/3337718-ftd-dives-after-warning-wont-meet-financial-covenant-terms?source=tweet\" data-url=\"https://seekingalpha.com/news/3337718-ftd-dives-after-warning-wont-meet-financial-covenant-terms\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337716\" data-ts=\"1520538951\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EA\" target=\"_blank\">EA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337716-videogame-stocks-higher-white-house-summit-eyes-violence\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Videogame stocks higher as White House summit eyes violence</a></h4><ul>   <li>Stocks of big videogame makers are mostly higher heading into a White House meeting taking up the subject of whether games are a cause of violence.</li>    <li>Electronic Arts (NASDAQ:<a href='https://seekingalpha.com/symbol/EA' title='Electronic Arts Inc.'>EA</a>) is <font color='green'>up 1.2%</font>; Take-Two Interactive Software (NASDAQ:<a href='https://seekingalpha.com/symbol/TTWO' title='Take-Two Interactive Software, Inc.'>TTWO</a>) is <font color='green'>up 1.8%</font>; Microsoft (NASDAQ:<a href='https://seekingalpha.com/symbol/MSFT' title='Microsoft Corporation'>MSFT</a>) is <font color='green'>up 0.4%</font>, Sony (NYSE:<a href='https://seekingalpha.com/symbol/SNE' title='Sony Corporation'>SNE</a>) <font color='green'>up 0.9%</font>, and Nintendo (<a href='https://seekingalpha.com/symbol/NTDOY' title='Nintendo Co., Ltd. ADR'>OTCPK:NTDOY</a>) <font color='green'>up 2.5%</font>. Activision Blizzard (NASDAQ:<a href='https://seekingalpha.com/symbol/ATVI' title='Activision Blizzard, Inc'>ATVI</a>) is <font color='green'>up 3.5%</font> alongside the reveal of an Oct. 12 release date for its next franchise entry <i>Call of Duty: Black Ops 4.</i></li>    <li>The meeting was set to include members of Congress (Sen. Marco Rubio, and Reps. Vicky Hartzler and Martha Roby, all Republicans) along with industry reps (Strauss Zelnick, CEO of Take-Two's Rockstar Games, and Robert Altman, CEO of Bethesda Softworks parent ZeniMax Media) and critics like Dave Grossman, an author who referred to some games as \"murder simulators,\" and Media Research Center's Brent Bozell and Parents Television Council's Melissa Henson.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3337716\" data-linked=\"Videogame stocks higher as White House summit eyes violence\" data-tweet=\"$EA $EA $TTWO - Videogame stocks higher as White House summit eyes violence https://seekingalpha.com/news/3337716-videogame-stocks-higher-white-house-summit-eyes-violence?source=tweet\" data-url=\"https://seekingalpha.com/news/3337716-videogame-stocks-higher-white-house-summit-eyes-violence\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>76&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337715\" data-ts=\"1520538904\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RNVA\" target=\"_blank\">RNVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337715-technology-top-gainers-losers-of-2_55-pm-3-8-18\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2.55 pm (3/8/18)</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/RNVA' title='Rennova Health, Inc.'>OTCPK:RNVA</a> <font color='green'>+41%</font>. <a href='https://seekingalpha.com/symbol/NETE' title='Net Element International, Inc.'>NETE</a> <font color='green'>+28%</font>. <a href='https://seekingalpha.com/symbol/CMTL' title='Comtech Telecommunications Corp.'>CMTL</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/UMC' title='United Microelectronics Corporation'>UMC</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/OKTA' title='Okta, Inc.'>OKTA</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/MEET' title='The Meet Group, Inc.'>MEET</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/PRGS' title='Progress Software Corporation'>PRGS</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/INAP' title='Internap Network Services Corporation'>INAP</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/CAMP' title='CalAmp Corp.'>CAMP</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/INPX' title='Inpixon'>INPX</a> <font color='red'>-6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3337715\" data-linked=\"Technology - Top Gainers / Losers as of 2.55 pm (3/8/18)\" data-tweet=\"$RNVA $RNVA $NETE - Technology - Top Gainers / Losers as of 2.55 pm (3/8/18) https://seekingalpha.com/news/3337715-technology-top-gainers-losers-of-2_55-pm-3-8-18?source=tweet\" data-url=\"https://seekingalpha.com/news/3337715-technology-top-gainers-losers-of-2_55-pm-3-8-18\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337709\" data-ts=\"1520537641\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TECD\" target=\"_blank\">TECD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337709-tech-dataminus-18_2-on-q4-report-downside-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tech Data -18.2% on Q4 report with downside guidance</a></h4><ul><li>        Tech Data (NASDAQ:<a href='https://seekingalpha.com/symbol/TECD' title='Tech Data Corporation'>TECD</a>) shares continue to sink after this morning&rsquo;s Q4 results beat on EPS and revenue but included downside revenue guidance. Q1 guidance has revenue from $8B to $8.3B (consensus: $8.52B) and EPS from $1.30 to $1.60 (may not be comparable to consensus of $1.97).</li><li>               During the earnings call, management said that &ldquo;the guidance reflects the increasingly competitive market environment\" that started in the latter part of Q2.&nbsp;</li><li>               Tech Data also found out late last FY that a few key vendors would alter their existing programs due to the constricted environment, which would lower margins for distribution partners.&nbsp;</li><li>                  Non-GAAP operating income revised from flat to low-single-digits in FY1.    </li><li>               Tech Data expects the new revenue recognition standards to reduce sales by 7% this year.&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/17096134-tech-data-corporation-reports-fourth-quarter-fiscal-year-2018-results\" target=\"_blank\">Press release</a>&nbsp;</li><li>               Earnings call <a href=\"https://seekingalpha.com/article/4154642-tech-datas-tecd-ceo-bob-dutkowsky-q4-2018-results-earnings-call-transcript\" target=\"_blank\">transcript</a>&nbsp;</li><li>               Tech Data shares are&nbsp;<font color='red'>down 18.2%</font>.&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3337423-tech-data-beats-0_01-beats-revenue\" target=\"_blank\">Tech Data beats by $0.01, beats on revenue</a> (March 8)</li></ul><div class=\"tiny-share-widget\" data-id=\"3337709\" data-linked=\"Tech Data -18.2% on Q4 report with downside guidance\" data-tweet=\"$TECD - Tech Data -18.2% on Q4 report with downside guidance https://seekingalpha.com/news/3337709-tech-dataminus-18_2-on-q4-report-downside-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3337709-tech-dataminus-18_2-on-q4-report-downside-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:34 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337706\" data-ts=\"1520536212\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JAGX\" target=\"_blank\">JAGX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337706-jaguar-health-spikes-140\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jaguar Health spikes 140%</a></h4><ul><li>Nano cap Jaguar Health (<a href='https://seekingalpha.com/symbol/JAGX' title='Jaguar Animal Health, Inc.'>JAGX</a> <font color='green'>+139.7%</font>) rockets on massive turnover of 150M shares. No particular news accounts for the action.</li><li>Last month, it filed a <a href=\"https://www.sec.gov/Archives/edgar/data/1585608/000110465918008792/a18-4000_1424b3.htm\" target=\"_blank\">prospectus </a>for the potential sale of up to ~6M shares held by current investors.</li><li>Last week, subsidiary Napo Pharmaceuticals inked an <a href=\"https://www.sec.gov/Archives/edgar/data/1585608/000110465918014310/a18-7171_3ex99d1.htm\" target=\"_blank\">agreement </a>with pharmacy services provider Transition Patient Services aimed at expanding patient access to HIV-related diarrhea med <a href=\"https://www.mytesi.com/\" target=\"_blank\">Mytesi </a>(crofelemer).</li></ul><div class=\"tiny-share-widget\" data-id=\"3337706\" data-linked=\"Jaguar Health spikes 140%\" data-tweet=\"$JAGX - Jaguar Health spikes 140% https://seekingalpha.com/news/3337706-jaguar-health-spikes-140?source=tweet\" data-url=\"https://seekingalpha.com/news/3337706-jaguar-health-spikes-140\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337705\" data-ts=\"1520536115\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIDU\" target=\"_blank\">BIDU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337705-baidu-consolidates-departments-to-streamline-smart-hardware\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Baidu consolidates departments to streamline smart hardware</a></h4><ul><li>        Baidu (NASDAQ:<a href='https://seekingalpha.com/symbol/BIDU' title='Baidu, Inc.'>BIDU</a>) will <a href=\"https://www.chinamoneynetwork.com/2018/03/07/baidu-sets-new-department-push-ahead-smart-hardware-business\" target=\"_blank\">consolidate three departments</a> into one to streamline its smart hardware businesses.</li><li>               The new Smart Living Group will house the former DuerOS Business Unit (houses the DuerOS conversation-based AI platform), Raven Studio (smart hardware business acquired last year), and the Baidu Hardware Ecological Channel Department.&nbsp;</li><li>               Overseeing the Smart Living Group? Former Microsoft global executive VP Lu Qi. &nbsp;&nbsp;</li><li>               Baidu shares are&nbsp;<font color='red'>down 0.5%</font>&nbsp;to $255.96 with a 52-week range of $166 to $274.97.&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3336248-venture-capital-deals-week\" target=\"_blank\">Venture capital deals of the week</a> (March 3)</li></ul><div class=\"tiny-share-widget\" data-id=\"3337705\" data-linked=\"Baidu consolidates departments to streamline smart hardware\" data-tweet=\"$BIDU - Baidu consolidates departments to streamline smart hardware https://seekingalpha.com/news/3337705-baidu-consolidates-departments-to-streamline-smart-hardware?source=tweet\" data-url=\"https://seekingalpha.com/news/3337705-baidu-consolidates-departments-to-streamline-smart-hardware\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337702\" data-ts=\"1520535622\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZN\" target=\"_blank\">ZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337702-energy-materials-top-gainers-losers-of-2-00-pm-3-8-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm (3/8/2018)</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ZN' title='Zion Oil & Gas Inc'>ZN</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/ANW' title='Aegean Marine Petroleum Network Inc.'>OTC:ANW</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/TREC' title='Trecora Resources'>TREC</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/RKDA' title='Arcadia Biosciences'>RKDA</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/GPRK' title='GeoPark Ltd.'>GPRK</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CEI' title='Camber Energy, Inc.'>CEI</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/PQ' title='PetroQuest Energy Inc.'>PQ</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/CENX' title='Century Aluminum Company'>CENX</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/PEIX' title='Pacific Ethanol, Inc.'>PEIX</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/FMSA' title='Fairmount Santrol, Inc.'>FMSA</a> <font color='red'>-7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3337702\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm (3/8/2018)\" data-tweet=\"$ZN $ZN $ANW - Energy/Materials - Top Gainers / Losers as of 2:00 pm (3/8/2018) https://seekingalpha.com/news/3337702-energy-materials-top-gainers-losers-of-2-00-pm-3-8-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3337702-energy-materials-top-gainers-losers-of-2-00-pm-3-8-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337701\" data-ts=\"1520535178\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DXCM\" target=\"_blank\">DXCM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337701-dexcom-comes-up-short-in-challenge-to-waveform-patents-shares-down-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dexcom comes up short in challenge to WaveForm patents; shares down 1%</a></h4><ul><li>AgaMatrix Holdings LLC subsidiary WaveForm Technologies <a href=\"https://www.prnewswire.com/news-releases/waveform-technologies-receives-favorable-decision-on-critical-glucose-monitoring-patents-300610961.html\" target=\"_blank\">announces </a>that the U.S. Patent Trial and Appeal Board &#40;PTAB&#41; has ruled that two U.S. patents challenged by Dexcom (<a href='https://seekingalpha.com/symbol/DXCM' title='DexCom, Inc.'>DXCM</a> <font color='red'>-1.3%</font>) are not invalid.</li><li>Specifically, the PTAB found that three claims under WaveForm's U.S. Patent No. 7,146,202 and all challenged claims under No. 8,187,433 are not invalid. Dexcom's challenge to a third patent remains pending.</li><li>WaveForm sued Dexcom in 2016 in an Oregon court accusing Dexcom of infringing on the three patents in question, all related to sensor design and methodology. The case has been on hold for a year pending the PTAB decisions.</li></ul><div class=\"tiny-share-widget\" data-id=\"3337701\" data-linked=\"Dexcom comes up short in challenge to WaveForm patents; shares down 1%\" data-tweet=\"$DXCM - Dexcom comes up short in challenge to WaveForm patents; shares down 1% https://seekingalpha.com/news/3337701-dexcom-comes-up-short-in-challenge-to-waveform-patents-shares-down-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3337701-dexcom-comes-up-short-in-challenge-to-waveform-patents-shares-down-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:52 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337697\" data-ts=\"1520532689\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WJAFF\" target=\"_blank\">WJAFF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337697-westjet-airlinesminus-7-ceo-gregg-saretsky-retires-unexpectedly\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WestJet Airlines -7% as CEO Gregg Saretsky retires unexpectedly</a></h4><ul>     <li>WestJet Airlines (<a href='https://seekingalpha.com/symbol/WJAFF' title='WestJet Airlines Ltd.'>OTC:WJAFF</a> <font color='red'>-6.9%</font>) plunges after cutting its forecast for a key revenue metric and announcing the <a href=\"http://business.financialpost.com/transportation/airlines/westjet-airlines-chief-executive-gregg-saretsky-retires-replaced-by-ed-sims\" target=\"_blank\">surprise retirement</a> of CEO Gregg Saretsky.</li>     <li>WestJet&rsquo;s executive VP of commercial Ed Sims as appointed as the new President and CEO, effective  immediately; Saretsky led the company for eight years.</li>     <li>&ldquo;The change in leadership continues to <a href=\"https://www.reuters.com/article/westjetairlines-ceo/update-2-westjet-shares-fall-on-forecast-cut-ceo-exit-idUSL4N1QQ42V\" target=\"_blank\">add to our concern</a> around future execution of ULCC [ultra low-cost carrier Swoop] and widebody strategy,&rdquo; says equity research firm Alta Corp.</li><li>A labor battle has been brewing in recent weeks with the Air Line Pilots Association, which called for  fellow pilots unions to impose a so-called &ldquo;recruitment ban&rdquo; on Swoop.</li>     <li>Also, the Canadian carrier says it expects revenue per available seat mile to rise by 2.5%-3.5% in the current quarter, down from its previous forecast of 4.5%-5.5%, due to harsh weather conditions.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3337697\" data-linked=\"WestJet Airlines -7% as CEO Gregg Saretsky retires unexpectedly\" data-tweet=\"$WJAFF - WestJet Airlines -7% as CEO Gregg Saretsky retires unexpectedly https://seekingalpha.com/news/3337697-westjet-airlinesminus-7-ceo-gregg-saretsky-retires-unexpectedly?source=tweet\" data-url=\"https://seekingalpha.com/news/3337697-westjet-airlinesminus-7-ceo-gregg-saretsky-retires-unexpectedly\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:11 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337694\" data-ts=\"1520532342\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNAP\" target=\"_blank\">SNAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337694-snap-confirms-layoff-of-120-plus-engineering-workers-sharesminus-1_7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Snap confirms layoff of 120-plus engineering workers; shares -1.7%</a></h4><ul>   <li>Snap (<a href=\"http://seekingalpha.com/symbol/SNAP\" target=\"_blank\">SNAP</a> <font color='red'>-1.7%</font>) confirms a <a href=\"https://seekingalpha.com/news/3337242-snap-pares-gains-report-planning-biggest-layoff-yet\" target=\"_blank\">report of layoffs</a> from yesterday, saying it will <a href=\"https://twitter.com/alexeheath/status/971796737902960640\" target=\"_blank\">lay off \"just over 120\" workers</a>.</li>    <li>Those layoffs are landing on the engineering department, just a month after rolling out a redesign of flagship product Snapchat.</li>    <li>That hits about 10% of the engineering department.</li>    <li>\"Having high-performance, technically excellent, and appropriately aligned teams will be critical to building both a compelling product and a compelling culture for engineers,\" engineering head Jerry Hunter said in a note to employees, adding a streamlined team will keep a \"high technical bar.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3337694\" data-linked=\"Snap confirms layoff of 120-plus engineering workers; shares -1.7%\" data-tweet=\"$SNAP - Snap confirms layoff of 120-plus engineering workers; shares -1.7% https://seekingalpha.com/news/3337694-snap-confirms-layoff-of-120-plus-engineering-workers-sharesminus-1_7?source=tweet\" data-url=\"https://seekingalpha.com/news/3337694-snap-confirms-layoff-of-120-plus-engineering-workers-sharesminus-1_7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:05 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>38&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337692\" data-ts=\"1520532004\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGM\" target=\"_blank\">AGM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337692-financials-top-5-gainers-losers-of-1-00-pm-03-08-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM (03/08/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/AGM' title='Federal Agricultural Mortgage Corporation'>AGM</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/BKCC' title='BlackRock Capital Investment Corporation'>BKCC</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CRD.B' title='Crawford & Company'>CRD.B</a> <font color='red'>-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3337692\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM (03/08/2018)\" data-tweet=\"$AGM $AGM $BKCC - Financials - Top 5 Gainers / Losers as of 1:00 PM (03/08/2018) https://seekingalpha.com/news/3337692-financials-top-5-gainers-losers-of-1-00-pm-03-08-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3337692-financials-top-5-gainers-losers-of-1-00-pm-03-08-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337684\" data-ts=\"1520530681\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JAGX\" target=\"_blank\">JAGX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337684-midday-gainers-losers-3-8-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers (3/8/2018)</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/JAGX' title='Jaguar Animal Health, Inc.'>JAGX</a> <font color='green'>+97%</font>. <a href='https://seekingalpha.com/symbol/PCMI' title='PCM, Inc.'>PCMI</a> <font color='green'>+33%</font>. <a href='https://seekingalpha.com/symbol/ZSAN' title='Zosano Pharma'>ZSAN</a> <font color='green'>+30%</font>. <a href='https://seekingalpha.com/symbol/OGEN' title='Oragenics, Inc.'>OGEN</a> <font color='green'>+30%</font>. <a href='https://seekingalpha.com/symbol/JNCE' title='Jounce Therapeutics'>JNCE</a> <font color='green'>+25%</font>. <a href='https://seekingalpha.com/symbol/CMTL' title='Comtech Telecommunications Corp.'>CMTL</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/NETE' title='Net Element International, Inc.'>NETE</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/BBRG' title='Bravo Brio Restaurant Group, Inc.'>BBRG</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/ECYT' title='Endocyte, Inc.'>ECYT</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/PGNX' title='Progenics Pharmaceuticals Inc.'>PGNX</a> <font color='green'>+13%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/VBLT' title='VBL Therapeutics'>VBLT</a> <font color='red'>-63%</font>. <a href='https://seekingalpha.com/symbol/FTD' title='FTD Companies, Inc.'>FTD</a> <font color='red'>-38%</font>. <a href='https://seekingalpha.com/symbol/VISI' title='Volt Information Sciences, Inc.'>VISI</a> <font color='red'>-36%</font>. TRNC <font color='red'>-23%</font>. <a href='https://seekingalpha.com/symbol/RGLS' title='Regulus Therapeutics'>RGLS</a> <font color='red'>-22%</font>. <a href='https://seekingalpha.com/symbol/MYO' title='Myomo, Inc.'>MYO</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/XOMA' title='XOMA Corporation'>XOMA</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/MEET' title='The Meet Group, Inc.'>MEET</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/ZAGG' title='ZAGG Inc'>ZAGG</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/BIOS' title='BioScrip, Inc.'>BIOS</a> <font color='red'>-18%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3337684\" data-linked=\"Midday Gainers / Losers (3/8/2018)\" data-tweet=\"$JAGX $JAGX $PCMI - Midday Gainers / Losers (3/8/2018) https://seekingalpha.com/news/3337684-midday-gainers-losers-3-8-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3337684-midday-gainers-losers-3-8-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337679\" data-ts=\"1520530205\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ROIUF\" target=\"_blank\">ROIUF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337679-xpresspa-sells-group-mobile-in-latest-move-to-shed-assets\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">XpresSpa sells Group Mobile in latest move to shed assets</a></h4><ul>   <li>In an update on its move to shed noncore assets, XpresSpa (<a href=\"http://seekingalpha.com/symbol/XSPA\" target=\"_blank\">XSPA</a> <font color='green'>+1.8%</font>) says it <a href=\"https://seekingalpha.com/pr/17096601-xpresspa-divests-certain-key-non-core-assets\" target=\"_blank\">signed a deal yesterday</a> to sell rugged-device maker Group Mobile to Canada's Route 1 (<a href='https://seekingalpha.com/symbol/ROIUF' title='Route1 Inc.'>OTCQB:ROIUF</a>).</li>    <li>XpresSpa will get stock and warrants valued at $1M with an earn-out estimated at $1M, and it expects to get $0.75M on selling certain inventory.</li>    <li>The company also says it's settled outstanding litigation and made additional patent sales for cash of $0.4M.</li>    <li>It's noted that in October it sold power transfer/charging solutions developer FLI Charge, and in January sold some patents to Crypto Currency Patent Holdings Co. for about $1.25M.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3337679\" data-linked=\"XpresSpa sells Group Mobile in latest move to shed assets\" data-tweet=\"$ROIUF $ROIUF $XSPA - XpresSpa sells Group Mobile in latest move to shed assets https://seekingalpha.com/news/3337679-xpresspa-sells-group-mobile-in-latest-move-to-shed-assets?source=tweet\" data-url=\"https://seekingalpha.com/news/3337679-xpresspa-sells-group-mobile-in-latest-move-to-shed-assets\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337676\" data-ts=\"1520529791\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMRN\" target=\"_blank\">IMRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337676-immurons-immminus-124e-shows-encouraging-action-in-mid-stage-nash-study-shares-ahead-81\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Immuron&#39;s IMM-124E shows encouraging action in mid-stage NASH study; shares ahead 81%</a></h4><ul><li>Thinly traded nano cap Immuron Limited (<a href='https://seekingalpha.com/symbol/IMRN' title='Immuron Limited'>IMRN</a> <font color='green'>+81.4%</font>) is up on a 13x surge in volume, albeit on turnover of only 148K shares, on the heels of its <a href=\"https://seekingalpha.com/pr/17095966-immuron-reports-positive-results-nash-clinical-trial\" target=\"_blank\">announcement </a>of positive results from a <a href=\"https://clinicaltrials.gov/ct2/show/NCT02316717?spons=immuron&amp;phase=1&amp;rank=1\" target=\"_blank\">Phase 2 proof-of-concept clinical trial</a> assessing IMM-124E in 133 NASH patients, a reversal of fortune for the company after it reported unsuccessful results in July.</li><li>Top-line data showed treatment with IMM-124E (bovine colostrum) produced a statistically significant reduction in serum lipopolysaccharide &#40;LPS&#41; levels compared to placebo. LPS is associated with the progression of NASH. Specifically, 64.3% of patients in the treatment group experienced at least a 15% decrease in serum LPS versus 34.5% for placebo (p=0.018).</li><li>36.4% of patients receiving the higher dose (1200 mg) of IMM-124E experienced at least a 30% drop in average serum ALT (enzyme biomarker for liver damage) compared to 13.6% for placebo (p value not reported). In all patients, IMM-124E's effect on ALT did not statistically significantly separate from placebo (p=0.107). Parsing the data produced a statistically valid treatment effect in patients will elevated baseline ALT (p=0.048).</li><li>IMM-124E also produced statistically significant reductions in another enzyme called AST and a protein called CK-18, both of which are associated with liver damage (same criteria as ALT: proportion of patients vs. placebo).</li><li>IMM-124E is an orally available non-absorbable compound, bovine colostrum. containing polyclonal anti-LPS immunoglobulins. The company says its unique mechanism of action makes it a promising therapeutic candidate alone or in combination with other agents. <a href=\"https://www.mindbodygreen.com/articles/bovine-colostrum-101\" target=\"_blank\">Bovine colostrum</a> is the milky fluid produced by cows before giving birth and true milk appears.</li><li>Two other Phase 2 studies, in pediatric NAFLD and adults with severe alcoholic hepatitis, are ongoing.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3277704-immurons-nash-candidate-immminus-124e-fails-beat-placebo-mid-stage-study-shares-8-percent\" target=\"_blank\">Immuron's NASH candidate IMM-124E fails to beat placebo in mid-stage study; shares down 8%</a> (July 10, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3337676\" data-linked=\"Immuron&#39;s IMM-124E shows encouraging action in mid-stage NASH study; shares ahead 81%\" data-tweet=\"$IMRN - Immuron&#39;s IMM-124E shows encouraging action in mid-stage NASH study; shares ahead 81% https://seekingalpha.com/news/3337676-immurons-immminus-124e-shows-encouraging-action-in-mid-stage-nash-study-shares-ahead-81?source=tweet\" data-url=\"https://seekingalpha.com/news/3337676-immurons-immminus-124e-shows-encouraging-action-in-mid-stage-nash-study-shares-ahead-81\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:23 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337675\" data-ts=\"1520529502\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FFIV\" target=\"_blank\">FFIV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337675-f5-networksminus-5_5-amid-in-line-guidance-on-analyst-day\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">F5 Networks -5.5% amid in-line guidance on analyst day</a></h4><ul>   <li>F5 Networks (NASDAQ:<a href='https://seekingalpha.com/symbol/FFIV' title='F5 Networks, Inc.'>FFIV</a>) is sharply lower, <font color='red'>down 5.5%</font>, feeling likely investor disappointment on a fireworks-free analyst day that features middling guidance.</li>    <li>The company expects revenue growth of 2.5%-3.5% for fiscal 2018, along with gross margin of 84-85%, both largely in line with consensus.</li>    <li>It sees EPS at $9.40-$9.60 vs. consensus for $9.46, with growth in fiscal 2019-20 in low to mid single digits, and 2021-22 in mid- to high single digits.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3337675\" data-linked=\"F5 Networks -5.5% amid in-line guidance on analyst day\" data-tweet=\"$FFIV - F5 Networks -5.5% amid in-line guidance on analyst day https://seekingalpha.com/news/3337675-f5-networksminus-5_5-amid-in-line-guidance-on-analyst-day?source=tweet\" data-url=\"https://seekingalpha.com/news/3337675-f5-networksminus-5_5-amid-in-line-guidance-on-analyst-day\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:18 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337668\" data-ts=\"1520528631\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/REVG\" target=\"_blank\">REVG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337668-consumer-top-gainers-losers-of-12-00-pm-3-8-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm (3/8/2018)</a></h4><ul><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/REVG' title='REV Group'>REVG</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/BREW' title='Craft Brew Alliance Inc'>BREW</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3337668\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm (3/8/2018)\" data-tweet=\"$REVG $REVG $BREW - Consumer - Top Gainers / Losers as of 12:00 pm (3/8/2018) https://seekingalpha.com/news/3337668-consumer-top-gainers-losers-of-12-00-pm-3-8-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3337668-consumer-top-gainers-losers-of-12-00-pm-3-8-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:03 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337666\" data-ts=\"1520528395\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/X\" target=\"_blank\">X</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337666-steel-stocks-lower-ahead-of-trump-tariff-announcement\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Steel stocks lower ahead of Trump tariff announcement</a></h4><ul>     <li>Steel and aluminum shares are broadly lower ahead of Pres. Trump's expected announcement on tariffs 3:30 ET this afternoon, as investors will see if the president's tone has changed at all from last week when he proclaimed a 25% tariff on imported steel and a 10% levy on aluminum.</li>     <li>Investors also may be concerned that U.S. Steel's decision to <a href=\"https://seekingalpha.com/news/3337119-u-s-steel-reopen-major-steelmaking-facility\" target=\"_blank\">restart two blast furnaces</a> at its Granite City Works is premature, although Credit Suisse analyst Curt Woodworth thinks the move <a href=\"https://www.barrons.com/articles/steel-stocks-are-falling-again-1520522648\" target=\"_blank\">should prove highly accretive to the company.</a></li>     <li>In reiterating his Outperform rating and raising his stock price target to $55 from $48, Woodworth says is strategic and makes sense regardless of where the U.S. finally comes down on tariffs, as \"payback should be rapid and U.S. Steel is already short on volume.\"</li>     <li><a href='https://seekingalpha.com/symbol/X' title='United States Steel Corporation'>X</a> <font color='red'>-2.6%</font>, <a href='https://seekingalpha.com/symbol/AKS' title='AK Steel Holding Corp'>AKS</a> <font color='red'>-3%</font>, <a href='https://seekingalpha.com/symbol/CMC' title='Commercial Metals Company'>CMC</a> <font color='red'>-3.6%</font>, <a href='https://seekingalpha.com/symbol/NUE' title='Nucor Corporation'>NUE</a> <font color='red'>-2.3%</font>, <a href='https://seekingalpha.com/symbol/STLD' title='Steel Dynamics, Inc.'>STLD</a> <font color='red'>-2.2%</font>, <a href='https://seekingalpha.com/symbol/ZEUS' title='Olympic Steel, Inc.'>ZEUS</a> <font color='red'>-1.9%</font>, <a href='https://seekingalpha.com/symbol/MT' title='ArcelorMittal'>MT</a> <font color='red'>-2.3%</font>, <a href='https://seekingalpha.com/symbol/SCHN' title='Schnitzer Steel Industries, Inc.'>SCHN</a> <font color='red'>-1.6%</font>, <a href='https://seekingalpha.com/symbol/WOR' title='Worthington Industries, Inc.'>WOR</a> <font color='red'>-1.6%</font>, <a href='https://seekingalpha.com/symbol/CENX' title='Century Aluminum Company'>CENX</a> <font color='red'>-8.5%</font>, <a href='https://seekingalpha.com/symbol/AA' title='Alcoa Corporation'>AA</a> <font color='red'>-1.4%</font>, <a href='https://seekingalpha.com/symbol/CSTM' title='Constellium Holdco B.V.'>CSTM</a> <font color='red'>-1.9%</font>, <a href='https://seekingalpha.com/symbol/KALU' title='Kaiser Aluminum Corporation'>KALU</a> <font color='red'>-1.5%</font>.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/SLX' title='VanEck Vectors Steel ETF'>SLX</a>, <a href='https://seekingalpha.com/symbol/JJU-OLD' title='iPath Dow Jones-UBS Aluminum Total Return Sub-IndexS ETN'>JJU-OLD</a>, <a href='https://seekingalpha.com/symbol/FOIL' title='iPath Pure Beta Aluminum ETN'>FOIL</a></li><li><strong>Update</strong>: The president is expected to sign <a href=\"https://www.marketwatch.com/story/trump-tariff-plan-expected-to-exempt-canada-mexico-after-house-republicans-protest-2018-03-08\" target=\"_blank\">a somewhat watered-down</a> - Canada and Mexico exempted - decree this afternoon.</li></ul><div class=\"tiny-share-widget\" data-id=\"3337666\" data-linked=\"Steel stocks lower ahead of Trump tariff announcement\" data-tweet=\"$X $X $AKS - Steel stocks lower ahead of Trump tariff announcement https://seekingalpha.com/news/3337666-steel-stocks-lower-ahead-of-trump-tariff-announcement?source=tweet\" data-url=\"https://seekingalpha.com/news/3337666-steel-stocks-lower-ahead-of-trump-tariff-announcement\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337663\" data-ts=\"1520527755\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPLK\" target=\"_blank\">SPLK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337663-splunkplus-1_1-on-argus-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Splunk +1.1% on Argus upgrade</a></h4><ul><li>Argus <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/18/03/11327180/data-analytics-firm-splunk-has-discounted-valuation-tak\" target=\"_blank\">upgrades</a> Splunk (NASDAQ:<a href='https://seekingalpha.com/symbol/SPLK' title='Splunk Inc.'>SPLK</a>) from Hold to Buy with a $120 price target, a 12% upside to yesterday&rsquo;s close.</li><li>Analyst Joseph Bonner cites Splunk&rsquo;s current discount compared to its peers, margin expansions, and its attractiveness as an acquisition target.</li><li>Bonner notes that revenue has &ldquo;slowed from the super-fast growth seen several years ago&rdquo; but margin has expanded with the growing scale.</li><li>Splunk shares are&nbsp;<font color='green'>up 1.1%</font>&nbsp;to $106.77.</li></ul><div class=\"tiny-share-widget\" data-id=\"3337663\" data-linked=\"Splunk +1.1% on Argus upgrade\" data-tweet=\"$SPLK - Splunk +1.1% on Argus upgrade https://seekingalpha.com/news/3337663-splunkplus-1_1-on-argus-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3337663-splunkplus-1_1-on-argus-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:49 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337662\" data-ts=\"1520527369\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TI\" target=\"_blank\">TI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337662-report-elliott-looking-to-oust-vivendi-directors-telecom-italia\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Report: Elliott looking to oust Vivendi directors at Telecom Italia</a></h4><ul>   <li>Telecom Italia (NYSE:<a href='https://seekingalpha.com/symbol/TI' title='Telecom Italia S.P.A.'>TI</a>) is <font color='green'>up 3.6%</font> after a report has activist Elliott Management taking aim at the company with an eye to removing directors that were named by France's Vivendi (<a href='https://seekingalpha.com/symbol/VIVHY' title='Vivendi SA ADR'>OTCPK:VIVHY</a>).</li>    <li>Elliott wants to remove all five TI boardmembers that Vivendi named, including the chairman and CEO, <i>Il Sole</i> reports, saying the firm will submit Italian names instead.</li>    <li>It's also seeking a separation and listing of TI's network, in the interest of both shareholders and the country.</li>    <li>Elliott had reported holding ordinary and saving shares of Telecom Italia but that its stake fell below official thresholds requiring a report to regulators; it's said it won't seek control of the company.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3337662\" data-linked=\"Report: Elliott looking to oust Vivendi directors at Telecom Italia\" data-tweet=\"$TI $TI $VIVHY - Report: Elliott looking to oust Vivendi directors at Telecom Italia https://seekingalpha.com/news/3337662-report-elliott-looking-to-oust-vivendi-directors-telecom-italia?source=tweet\" data-url=\"https://seekingalpha.com/news/3337662-report-elliott-looking-to-oust-vivendi-directors-telecom-italia\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337660\" data-ts=\"1520526958\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VRTHF\" target=\"_blank\">VRTHF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337660-veritas-signs-loi-to-acquire-cannabis-extract-producer-3-carbon-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Veritas signs LOI to acquire cannabis extract producer 3 Carbon; shares up 2%</a></h4><ul><li>Veritas Pharma (<a href='https://seekingalpha.com/symbol/VRTHF' title='Veritas Pharma Inc'>OTCPK:VRTHF</a> <font color='green'>+2.4%</font>) inks a <a href=\"https://seekingalpha.com/pr/17096061-veritas-pharma-signs-letter-intent-3-carbon-extractions-inc\" target=\"_blank\">non-binding Letter of Intent</a> &#40;LOI&#41; with 3 Carbon Extractions outlining the terms and conditions for Veritas to acquire the cannabis extract producer.</li><li>The company believes Carbon can benefit from Cannevert Therapeutics' Health Canada Dealer License under which it is supplying cannabis strains for Veritas' clinical trials. Cannevert has agreed to help with the preclinical and clinical research on Carbon's extracts.</li><li>Cannabis extracts are expected to be legalized in Canada next year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3337660\" data-linked=\"Veritas signs LOI to acquire cannabis extract producer 3 Carbon; shares up 2%\" data-tweet=\"$VRTHF - Veritas signs LOI to acquire cannabis extract producer 3 Carbon; shares up 2% https://seekingalpha.com/news/3337660-veritas-signs-loi-to-acquire-cannabis-extract-producer-3-carbon-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3337660-veritas-signs-loi-to-acquire-cannabis-extract-producer-3-carbon-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337659\" data-ts=\"1520526791\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IBM\" target=\"_blank\">IBM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337659-ibm-releases-longer-term-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">IBM releases longer-term outlook</a></h4><ul><li>        IBM&rsquo;s (NYSE:<a href='https://seekingalpha.com/symbol/IBM' title='International Business Machines Corporation'>IBM</a>) <a href=\"https://seekingalpha.com/filing/3927792\" target=\"_blank\">investor briefing</a> includes a longer-term model with an unspecified time frame.</li><li>                  The model is compared to results from the last three years.    </li><li>               Revenue expected up in the low single-digits, EPS up in the high single-digits, and pre-tax income in the mid single-digits.&nbsp;</li><li>               FCF realization expected over 90% compared to the past 104%. Capital expense seen at a steady rate compared to the $11B and acquisition spend strategically aligned with the $10B in the past years.&nbsp;</li><li>               Dividends expected to increase annually from the $16B and share repurchases to reduce the share count by about 2% annually.&nbsp;</li><li>                  IBM shares are&nbsp;<font color='red'>down 1.2%</font>&nbsp;to $156.46.&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3337659\" data-linked=\"IBM releases longer-term outlook\" data-tweet=\"$IBM - IBM releases longer-term outlook https://seekingalpha.com/news/3337659-ibm-releases-longer-term-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3337659-ibm-releases-longer-term-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>80&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337656\" data-ts=\"1520526288\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WDDMF\" target=\"_blank\">WDDMF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337656-weedmd-and-phivida-team-up-to-develop-cannabis-infused-beverages\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WeedMD and Phivida team up to develop cannabis-infused beverages</a></h4><ul><li>Medical cannabis producer WeedMD (<a href='https://seekingalpha.com/symbol/WDDMF' title='WeedMD Inc'>OTCPK:WDDMF</a> <font color='red'>-4.5%</font>) and hemp products developer Phivida Holdings (<a href='https://seekingalpha.com/symbol/PHVAF' title='Phivida Holdings Inc.'>OTCQX:PHVAF</a> <font color='green'>+3.6%</font>) have agreed to form a <a href=\"https://seekingalpha.com/pr/17096817-weedmd-phivida-enter-joint-venture-cannabis-infused-beverages\" target=\"_blank\">joint venture</a> &#40;JV&#41; aimed at producing cannabis-infused beverages. The JV company will do business under the name Cannabis Beverages with production at WeedMD's Strathroy, Ontario location.</li><li>Financial terms are not disclosed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3337656\" data-linked=\"WeedMD and Phivida team up to develop cannabis-infused beverages\" data-tweet=\"$WDDMF $WDDMF $PHVAF - WeedMD and Phivida team up to develop cannabis-infused beverages https://seekingalpha.com/news/3337656-weedmd-and-phivida-team-up-to-develop-cannabis-infused-beverages?source=tweet\" data-url=\"https://seekingalpha.com/news/3337656-weedmd-and-phivida-team-up-to-develop-cannabis-infused-beverages\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337652\" data-ts=\"1520525447\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FNV\" target=\"_blank\">FNV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337652-franco-nevadaminus-4-following-q4-earnings-miss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Franco-Nevada -4% following Q4 earnings miss</a></h4><ul>     <li>Franco-Nevada (<a href='https://seekingalpha.com/symbol/FNV' title='Franco-Nevada Corporation'>FNV</a> <font color='red'>-4.6%</font>) is sharply lower after failing to meet analyst expectations for <a href=\"https://seekingalpha.com/news/3337345-franco-nevada-misses-0_04-misses-revenue\" target=\"_blank\">Q4 earnings</a> and revenues, although it says it achieved a new sales record of 497.7K gold equiv. oz., a 7.2% Y/Y increase.</li>     <li>For FY 2018, FNV expects attributable royalty and stream production to total 460K-490K gold equiv. oz. from its mineral assets, including 310K-330K gold equiv. oz. from its various stream agreements with no GEOs assumed from Cobre Panama.</li>     <li>In its five-year outlook, FNV expects its existing portfolio to generate 565K-595K gold equiv. oz. by 2022; during 2019-21, scheduled fixed ounce payments from Midas/Fire Creek, Karma and Sabodala are expected to step down to longer-term royalty payments or stream deliveries.</li></ul><div class=\"tiny-share-widget\" data-id=\"3337652\" data-linked=\"Franco-Nevada -4% following Q4 earnings miss\" data-tweet=\"$FNV - Franco-Nevada -4% following Q4 earnings miss https://seekingalpha.com/news/3337652-franco-nevadaminus-4-following-q4-earnings-miss?source=tweet\" data-url=\"https://seekingalpha.com/news/3337652-franco-nevadaminus-4-following-q4-earnings-miss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337658\" data-ts=\"1520525282\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASNT\" target=\"_blank\">ASNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337658-arias-intel-reduces-outstanding-debt-obligations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arias Intel reduces outstanding debt obligations</a></h4><ul>     <li>Arias Intel (<a href='https://seekingalpha.com/symbol/ASNT' title='Arias Intel Corp.'>OTCPK:ASNT</a> <font color='green'>+17.5%</font>) announced that it has reduced its outstanding debt obligations. The company, on Feb. 14, 2018, had entered into settlement agreement &amp; Mutual general release with a certain debt holder.</li>     <li>In addition to the settlement agreement, the Company has reached agreements with holders of $0.356M in convertible notes to convert their outstanding debt to equity shares of the Company&rsquo;s common stock.</li>     <li>The Company is also in negotiations with another institutional convertible note holder to convert their debt into shares of the Company&rsquo;s commons stock, further reducing its debt obligations.</li>     <li>Arias expects to generate revenue from our mobile apps over the next few months.</li>     <li><a href=\"https://seekingalpha.com/pr/17096778-arias-intel-reduces-outstanding-debt-obligations\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3337658\" data-linked=\"Arias Intel reduces outstanding debt obligations\" data-tweet=\"$ASNT - Arias Intel reduces outstanding debt obligations https://seekingalpha.com/news/3337658-arias-intel-reduces-outstanding-debt-obligations?source=tweet\" data-url=\"https://seekingalpha.com/news/3337658-arias-intel-reduces-outstanding-debt-obligations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:08 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337651\" data-ts=\"1520525135\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTES\" target=\"_blank\">NTES</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337651-netease-brings-crusaders-of-light-to-steam-new-content\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NetEase brings &#39;Crusaders of Light&#39; to Steam with new content</a></h4><ul>   <li>NetEase (<a href=\"http://seekingalpha.com/symbol/NTES\" target=\"_blank\">NTES</a> <font color='green'>+2%</font>) has made its massive multiplayer game Crusaders of Light <a href=\"https://seekingalpha.com/pr/17096742-mmorpg-crusaders-light-launches-steam-new-server-major-content-update\" target=\"_blank\">available on Steam</a> alongside a new global server and a content addition.</li>    <li>The role-playing game features more than 300 hours of available gameplay; the new \"Surge of Elements\" update adds a new team raid, a new dungeon, two new bosses and a new class.</li>    <li>Aside from Steam, the game is available on the App Store, Google Play store, and Facebook Gameroom.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3337651\" data-linked=\"NetEase brings &#39;Crusaders of Light&#39; to Steam with new content\" data-tweet=\"$NTES - NetEase brings &#39;Crusaders of Light&#39; to Steam with new content https://seekingalpha.com/news/3337651-netease-brings-crusaders-of-light-to-steam-new-content?source=tweet\" data-url=\"https://seekingalpha.com/news/3337651-netease-brings-crusaders-of-light-to-steam-new-content\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337648\" data-ts=\"1520524818\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OGEN\" target=\"_blank\">OGEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337648-healthcare-top-5-gainers-losers-of-11-00-3-8-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am (3/8/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/OGEN' title='Oragenics, Inc.'>OGEN</a> <font color='green'>+25%</font>. <a href='https://seekingalpha.com/symbol/ZSAN' title='Zosano Pharma'>ZSAN</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/JNCE' title='Jounce Therapeutics'>JNCE</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/AEMD' title='Aethlon Medical, Inc.'>AEMD</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/PGNX' title='Progenics Pharmaceuticals Inc.'>PGNX</a> <font color='green'>+13%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/VBLT' title='VBL Therapeutics'>VBLT</a> <font color='red'>-61%</font>. <a href='https://seekingalpha.com/symbol/RGLS' title='Regulus Therapeutics'>RGLS</a> <font color='red'>-22%</font>. <a href='https://seekingalpha.com/symbol/MYO' title='Myomo, Inc.'>MYO</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/XOMA' title='XOMA Corporation'>XOMA</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/BIOS' title='BioScrip, Inc.'>BIOS</a> <font color='red'>-12%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3337648\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am (3/8/2018)\" data-tweet=\"$OGEN $OGEN $ZSAN - Healthcare - Top 5 Gainers / Losers as of 11:00 am (3/8/2018) https://seekingalpha.com/news/3337648-healthcare-top-5-gainers-losers-of-11-00-3-8-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3337648-healthcare-top-5-gainers-losers-of-11-00-3-8-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337644\" data-ts=\"1520524442\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLBS\" target=\"_blank\">CLBS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337644-caladrius-reports-preliminary-data-from-mid-stage-study-of-t1d-candidate-clbs03-shares-down-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Caladrius reports &quot;preliminary data&quot; from mid-stage study of T1D candidate CLBS03; shares down 5%</a></h4><ul><li>Thinly traded nano cap Caladrius Biosciences (<a href='https://seekingalpha.com/symbol/CLBS' title='Caladrius Biosciences, Inc.'>CLBS</a> <font color='red'>-4.9%</font>) is down on average volume on the heels of its <a href=\"https://seekingalpha.com/pr/17096339-caladrius-biosciences-reports-interim-analysis-phase-2-t-rex-trial-clbs03-type-1-diabetes\" target=\"_blank\">announcement </a>of interim data from its Phase 2 clinical trial, T-Rex, assessing CLBS03 in adolescents with recent-onset type 1 diabetes (T1D).</li><li>The company says CLBS03 remains well-tolerated and that a positive outcome for efficacy \"remains a statistical possibility.\"</li><li>12-month follow-up data should be available in early 2019.</li><li>CLBS03 is a autologous cell therapy consisting of the patient's own T cells that have been expanded and re-engineered via a proprietary method.</li></ul><div class=\"tiny-share-widget\" data-id=\"3337644\" data-linked=\"Caladrius reports &quot;preliminary data&quot; from mid-stage study of T1D candidate CLBS03; shares down 5%\" data-tweet=\"$CLBS - Caladrius reports &quot;preliminary data&quot; from mid-stage study of T1D candidate CLBS03; shares down 5% https://seekingalpha.com/news/3337644-caladrius-reports-preliminary-data-from-mid-stage-study-of-t1d-candidate-clbs03-shares-down-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3337644-caladrius-reports-preliminary-data-from-mid-stage-study-of-t1d-candidate-clbs03-shares-down-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337642\" data-ts=\"1520524044\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZAGG\" target=\"_blank\">ZAGG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337642-zagg-falls-sharply-after-soft-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zagg falls sharply after soft guidance</a></h4><ul> <li>Zagg (NASDAQ:<a href='https://seekingalpha.com/symbol/ZAGG' title='ZAGG Inc'>ZAGG</a>) is in reverse after soft guidance and the resignation of the company's CEO.</li><li>The company expects FY18 revenue of $550M to $570M vs. $569M consensus.</li> <li>Zagg was also hit by a <a href=\"https://www.streetinsider.com/Analyst+Comments/B.RileyFBR+Downgrades+ZAGG+Incorporated+%28ZAGG%29+to+Neutral/13918868.html\" target=\"_blank\">downgrade</a> from B. Riley to Neutral from Buy on concerns over the company's decelerating growth amid a strong iPhone cycle.</li> <li>Zagg trades at its lowest level since last September.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3337274-zagg-misses-0_02-beats-revenue\" target=\"_blank\">Zagg misses by $0.02, beats on revenue</a> (March 7)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3337285-zagg-ceo-steps\" target=\"_blank\">ZAGG CEO steps down</a> (March 7)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3337642\" data-linked=\"Zagg falls sharply after soft guidance\" data-tweet=\"$ZAGG - Zagg falls sharply after soft guidance https://seekingalpha.com/news/3337642-zagg-falls-sharply-after-soft-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3337642-zagg-falls-sharply-after-soft-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337641\" data-ts=\"1520523779\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ERII\" target=\"_blank\">ERII</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337641-energy-recoveryplus-7-on-news-of-10m-stock-buyback-program\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy Recovery +7% on news of $10M stock buyback program</a></h4><ul>     <li>Energy Recovery (<a href='https://seekingalpha.com/symbol/ERII' title='Energy Recovery, Inc.'>ERII</a> <font color='green'>+7.1%</font>) opens with strong gains despite reporting below consensus <a href=\"https://seekingalpha.com/news/3337313-energy-recovery-misses-0_06-misses-revenue\" target=\"_blank\">Q4 earnings</a> and revenues, as its board approves a <a href=\"https://seekingalpha.com/pr/17096695-energy-recovery-announces-share-repurchase-program\" target=\"_blank\">$10M share repurchase program</a>.</li>     <li>\"Our business performed exceedingly well in 2017, generating positive cash flow to add to our already strong balance sheet,\" the company says in support of the buyback.</li>     <li>ERII says it set all-time highs during FY 2017 in revenues for both the water and oil and gas segments, as well as record full-year product and total gross margins, and expects the current expansion phase in the desalination business cycle to continue throughout 2018.</li></ul><div class=\"tiny-share-widget\" data-id=\"3337641\" data-linked=\"Energy Recovery +7% on news of $10M stock buyback program\" data-tweet=\"$ERII - Energy Recovery +7% on news of $10M stock buyback program https://seekingalpha.com/news/3337641-energy-recoveryplus-7-on-news-of-10m-stock-buyback-program?source=tweet\" data-url=\"https://seekingalpha.com/news/3337641-energy-recoveryplus-7-on-news-of-10m-stock-buyback-program\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337640\" data-ts=\"1520523654\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IDXG\" target=\"_blank\">IDXG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337640-four-new-bcbs-plans-on-board-interpace-thyroid-tests-shares-up-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Four new BCBS plans on board with Interpace thyroid tests; shares up 3%</a></h4><ul><li>Interpace Diagnostics Group (<a href='https://seekingalpha.com/symbol/IDXG' title='Interpace Diagnostics Group, Inc.'>IDXG</a> <font color='green'>+3%</font>) <a href=\"https://seekingalpha.com/pr/17096390-interpace-diagnostics-announces-additional-coverage-thyroid-tests\" target=\"_blank\">announces </a>that four additional Blue Cross Blue Shield plans will cover its ThyGenX and ThyraMIR tests. The four insurers, with over 5M members, are: BCBS of South Carolina, BCBS of Arizona, Wellmark BCBS of Iowa and WellMark BCBS of South Dakota.</li></ul><div class=\"tiny-share-widget\" data-id=\"3337640\" data-linked=\"Four new BCBS plans on board with Interpace thyroid tests; shares up 3%\" data-tweet=\"$IDXG - Four new BCBS plans on board with Interpace thyroid tests; shares up 3% https://seekingalpha.com/news/3337640-four-new-bcbs-plans-on-board-interpace-thyroid-tests-shares-up-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3337640-four-new-bcbs-plans-on-board-interpace-thyroid-tests-shares-up-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:40 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337639\" data-ts=\"1520523546\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRGS\" target=\"_blank\">PRGS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337639-progress-softwareminus-8_2-on-investor-exit-analyst-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Progress Software -8.2% on investor exit, analyst downgrade</a></h4><ul><li>        Hedge fund Praesidium Investment Management Company <a href=\"https://seekingalpha.com/filing/3926919\" target=\"_blank\">exits</a> most of its position in Progress Software (NASDAQ:<a href='https://seekingalpha.com/symbol/PRGS' title='Progress Software Corporation'>PRGS</a>).</li><li>               Praesidium&rsquo;s selling spree started in January and hit its peak on Monday with 3.76M.&nbsp;</li><li>               Analyst action: Benchmark cuts Progress Software from Buy to Sell after Praesidium&rsquo;s exit.&nbsp;</li><li>               Analyst Mark Schappel says the prior Buy was based on external matters related to disagreements between the company and the investor instead of business fundamentals.&nbsp;</li><li>               Price target slashed from $47 to $35 and Schappel expects the mid-30s range over time.&nbsp;</li><li>               Source: Briefing.com.&nbsp;</li><li>               Progress Software shares are&nbsp;<font color='red'>down 8.2%</font>&nbsp;to $40.74.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3337639\" data-linked=\"Progress Software -8.2% on investor exit, analyst downgrade\" data-tweet=\"$PRGS - Progress Software -8.2% on investor exit, analyst downgrade https://seekingalpha.com/news/3337639-progress-softwareminus-8_2-on-investor-exit-analyst-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3337639-progress-softwareminus-8_2-on-investor-exit-analyst-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:39 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337630\" data-ts=\"1520523446\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HOV\" target=\"_blank\">HOV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337630-hovanian-shares-down-6-after-earnings-miss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hovanian shares down 6% after earnings miss</a></h4><ul><li>FQ1 net loss of $30.8M or $0.21 per share vs. flat a year ago.. Revenues of $417.2M vs. $552M.</li><li>Homebuilding gross margin (incl. interest and land costs) of 14.8% up from 13.5% last year.</li><li>Consolidated lots controlled increased to 27,183 from 25,329 lots at end of last quarter.</li><li>Total liquidity at the end of the quarter was $292M.</li><li>CEO Ara Hovnanian notes the company's financing issues are now in the rearview mirror, and he expects FQ1 to mark the low point for the year.</li><li><a href=\"http://www.khov.com/investor-relations\" target=\"_blank\">Conference call at 11 ET</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3337589-hovnanian-misses-0_13-misses-revenue\" target=\"_blank\">Hovnanian misses by $0.13, misses on revenue</a> (March 8)</li><li><a href='https://seekingalpha.com/symbol/HOV' title='Hovnanian Enterprises, Inc.'>HOV</a>&nbsp;<font color='red'>down</font>&nbsp;<font color='red'>-6.4%</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3337630\" data-linked=\"Hovanian shares down 6% after earnings miss\" data-tweet=\"$HOV - Hovanian shares down 6% after earnings miss https://seekingalpha.com/news/3337630-hovanian-shares-down-6-after-earnings-miss?source=tweet\" data-url=\"https://seekingalpha.com/news/3337630-hovanian-shares-down-6-after-earnings-miss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337634\" data-ts=\"1520523066\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RWLK\" target=\"_blank\">RWLK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337634-rewalk-secures-20m-private-capital-raise-to-support-entry-china-shares-ahead-9\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ReWalk secures $20M private capital raise to support entry into China; shares ahead 9%</a></h4><ul><li>ReWalk Robotics (<a href='https://seekingalpha.com/symbol/RWLK' title='ReWalk Robotics'>RWLK</a> <font color='green'>+9.1%</font>) inks an <a href=\"https://seekingalpha.com/pr/17096164-rewalk-robotics-announces-20-million-strategic-investment-timwell-corporation-limited\" target=\"_blank\">agreement </a>with Hong Kong-based Timwell Corporation Limited for the direct placement of 16M common shares at $1.25 per share yielding $20M in proceeds.</li><li>Under the terms of the deal, the company and affiliates of Timwell will form a joint venture in China (including Macau and Hong Kong) to develop, manufacture and commercialize ReWalk's products. First up will be the Restore soft-suit exoskeleton for stroke patients in rehabilitation.</li></ul><div class=\"tiny-share-widget\" data-id=\"3337634\" data-linked=\"ReWalk secures $20M private capital raise to support entry into China; shares ahead 9%\" data-tweet=\"$RWLK - ReWalk secures $20M private capital raise to support entry into China; shares ahead 9% https://seekingalpha.com/news/3337634-rewalk-secures-20m-private-capital-raise-to-support-entry-china-shares-ahead-9?source=tweet\" data-url=\"https://seekingalpha.com/news/3337634-rewalk-secures-20m-private-capital-raise-to-support-entry-china-shares-ahead-9\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:31 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337633\" data-ts=\"1520522797\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OKTA\" target=\"_blank\">OKTA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337633-oktaplus-7_7-after-needham-ups-price-target-to-28-upside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Okta +7.7% after Needham ups price target to 28% upside</a></h4><ul><li>        Okta (NASDAQ:<a href='https://seekingalpha.com/symbol/OKTA' title='Okta, Inc.'>OKTA</a>)&nbsp;<font color='green'>pops 7.7%</font>&nbsp;after Needham boosts its price target from $38 to $50, a 28% upside on yesterday&rsquo;s close. &nbsp;</li><li>        Analyst Alex Henderson says that while the quarter&rsquo;s pre-release made broad strength &ldquo;reasonably well known,&rdquo; the actual report renewed enthusiasm.</li><li>               Firm maintains a Buy rating.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3337368-okta-beats-guides-high-record-q4\" target=\"_blank\">Okta beats and guides high in record Q4</a> (March 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3337633\" data-linked=\"Okta +7.7% after Needham ups price target to 28% upside\" data-tweet=\"$OKTA - Okta +7.7% after Needham ups price target to 28% upside https://seekingalpha.com/news/3337633-oktaplus-7_7-after-needham-ups-price-target-to-28-upside?source=tweet\" data-url=\"https://seekingalpha.com/news/3337633-oktaplus-7_7-after-needham-ups-price-target-to-28-upside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337621\" data-ts=\"1520521220\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRVS\" target=\"_blank\">CRVS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337621-corvus-prices-stock-offering-8_50-shares-down-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Corvus prices stock offering at $8.50, shares down 4%</a></h4><ul><li>Corvus Pharmaceuticals (<a href='https://seekingalpha.com/symbol/CRVS' title='Corvus Pharmaceuticals'>CRVS</a> <font color='red'>-3.8%</font>)&nbsp;<a href=\"https://seekingalpha.com/pr/17096755-corvus-pharmaceuticals-announces-pricing-public-offering-common-stock\" target=\"_blank\">prices </a>its public offering of ~7.06M shares of common stock at $8.50 per share. Closing date is March 12.</li></ul><div class=\"tiny-share-widget\" data-id=\"3337621\" data-linked=\"Corvus prices stock offering at $8.50, shares down 4%\" data-tweet=\"$CRVS - Corvus prices stock offering at $8.50, shares down 4% https://seekingalpha.com/news/3337621-corvus-prices-stock-offering-8_50-shares-down-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3337621-corvus-prices-stock-offering-8_50-shares-down-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337620\" data-ts=\"1520521117\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PCMI\" target=\"_blank\">PCMI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337620-pcm-spikes-after-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PCM spikes after earnings</a></h4><ul> <li>Investors are ignoring the earnings miss for PCM (<a href='https://seekingalpha.com/symbol/PCMI' title='PCM, Inc.'>PCMI</a> <font color='green'>+41.4%</font>) to focus on the underlying gain in commercial sales during the quarter. PCM expects 2018 revenue growth of 5%, which matched the expectations of analysts.</li> <li>B. Riley is helping a bit with sentiment today after hiking its price target on the services stock to $9 from $7.</li><li>Short covering could also be adding to the lift in share price.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3337295-pcm-eps-0_17\" target=\"_blank\">PCM EPS of $0.17</a> (March 7)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3337620\" data-linked=\"PCM spikes after earnings\" data-tweet=\"$PCMI - PCM spikes after earnings https://seekingalpha.com/news/3337620-pcm-spikes-after-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3337620-pcm-spikes-after-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337619\" data-ts=\"1520521083\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VRSN\" target=\"_blank\">VRSN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337619-cowen-reportedly-sees-verisign-tracking-below-estimates\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cowen reportedly sees Verisign tracking below estimates</a></h4><ul><li>        Cowen reportedly sees Verisign (NASDAQ:<a href='https://seekingalpha.com/symbol/VRSN' title='VeriSign, Inc.'>VRSN</a>) domain names add tracking at 1.5M compared to the 1.5M to 2M guidance, according to checks.</li><li>               Source: <a href=\"https://twitter.com/thenotablecalls\" target=\"_blank\">Notable Calls</a>&nbsp;</li><li>               Verisign shares are&nbsp;<font color='red'>down 0.7%</font>&nbsp;to $117.85.&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3337619\" data-linked=\"Cowen reportedly sees Verisign tracking below estimates\" data-tweet=\"$VRSN - Cowen reportedly sees Verisign tracking below estimates https://seekingalpha.com/news/3337619-cowen-reportedly-sees-verisign-tracking-below-estimates?source=tweet\" data-url=\"https://seekingalpha.com/news/3337619-cowen-reportedly-sees-verisign-tracking-below-estimates\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337616\" data-ts=\"1520520947\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337616-dovish-is-verdict-for-now-on-ecb\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dovish is the verdict (for now) on ECB</a></h4><ul><li>The euro (NYSEARCA:<a href='https://seekingalpha.com/symbol/FXE' title='CurrencyShares Euro Trust ETF'>FXE</a>) shot higher in the initial moments <a href=\"https://seekingalpha.com/news/3337505-euro-bond-yields-turn-higher-ecb\" target=\"_blank\">after the ECB policy decision</a> (no change) and statement, with traders seizing upon a modest change in tone surrounding the QE program.</li><li>On further reflection and amid Mario Draghi's post-meeting press conference, traders are now talking about the \"well past\" phrase - as in \"ECB interest rates to remain at their present levels for an extended period of time, and <strong>well past</strong>\" the end of QE.</li><li>The euro has turned lower vs. the dollar&nbsp;<font color='red'>by 0.3%</font>&nbsp;and the Stoxx 600 has moved from flat to&nbsp;<font color='green'>up 0.8%</font>. Bond yields across the Continent have also reversed to nicely lower on the session.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/FXE' title='CurrencyShares Euro Trust ETF'>FXE</a>, <a href='https://seekingalpha.com/symbol/VGK' title='Vanguard FTSE Europe ETF'>VGK</a>, <a href='https://seekingalpha.com/symbol/EUO' title='ProShares UltraShort Euro ETF'>EUO</a>, <a href='https://seekingalpha.com/symbol/HEDJ' title='WisdomTree Europe Hedged Equity ETF'>HEDJ</a>, <a href='https://seekingalpha.com/symbol/FEZ' title='SPDR EURO STOXX 50 ETF'>FEZ</a>, <a href='https://seekingalpha.com/symbol/EZU' title='iShares MSCI Eurozone ETF'>EZU</a>, <a href='https://seekingalpha.com/symbol/IEV' title='iShares Europe ETF'>IEV</a>, <a href='https://seekingalpha.com/symbol/ERO' title='iPath EUR/USD Exchange Rate ETN'>ERO</a>, <a href='https://seekingalpha.com/symbol/EPV' title='ProShares UltraShort FTSE Europe ETF'>EPV</a>, <a href='https://seekingalpha.com/symbol/IEUR' title='iShares Core MSCI Europe ETF'>IEUR</a>, <a href='https://seekingalpha.com/symbol/EURL' title='Direxion Daily FTSE Europe Bull 3x Shares ETF'>EURL</a>, <a href='https://seekingalpha.com/symbol/DRR' title='Market Vectors Double Short Euro ETN'>DRR</a>, <a href='https://seekingalpha.com/symbol/FEU' title='SPDR STOXX Europe 50 ETF'>FEU</a>, <a href='https://seekingalpha.com/symbol/ULE' title='ProShares Ultra Euro ETF'>ULE</a>, <a href='https://seekingalpha.com/symbol/DBEU' title='Deutsche X-trackers MSCI Europe Hedged Equity ETF'>DBEU</a>, <a href='https://seekingalpha.com/symbol/EUFX' title='ProShares Short Euro ETF'>EUFX</a>, <a href='https://seekingalpha.com/symbol/HEZU' title='iShares Currency Hedged MSCI EMU ETF'>HEZU</a>, <a href='https://seekingalpha.com/symbol/EEA' title='European Equity Fund'>EEA</a>, <a href='https://seekingalpha.com/symbol/URR' title='Market Vectors Double Long Euro ETN'>URR</a>, <a href='https://seekingalpha.com/symbol/FEEU' title='Barclays ETN+ FI Enhanced Europe 50 ETN'>FEEU</a>, <a href='https://seekingalpha.com/symbol/FEP' title='First Trust Europe AlphaDEX ETF'>FEP</a>, <a href='https://seekingalpha.com/symbol/UPV' title='ProShares Ultra FTSE Europe ETF'>UPV</a>, <a href='https://seekingalpha.com/symbol/ADRU' title='BLDRS Europe 100 ADR Index ETF'>ADRU</a>, <a href='https://seekingalpha.com/symbol/FEUZ' title='First Trust Eurozone AlphaDex ETF'>FEUZ</a>, <a href='https://seekingalpha.com/symbol/DBEZ' title='Deutsche X-trackers MSCI EMU Hedged Equity ETF'>DBEZ</a>, <a href='https://seekingalpha.com/symbol/FIEU' title='Credit Suisse FI Enhanced Europe 50 ETN'>FIEU</a>, <a href='https://seekingalpha.com/symbol/DEZU' title='iShares Adaptive Currency Hedged MSCI Eurozone ETF'>DEZU</a>, <a href='https://seekingalpha.com/symbol/GSEU' title='Goldman Sachs ActiveBeta Europe Equity ETF'>GSEU</a>, <a href='https://seekingalpha.com/symbol/PTEU' title='Pacer Trendpilo European Index ETF'>PTEU</a>, <a href='https://seekingalpha.com/symbol/FIEE' title='UBS AG FI Enhanced Europe 50 ETN'>FIEE</a>, <a href='https://seekingalpha.com/symbol/HFXE' title='IQ 50 Percent Hedged FTSE Europe ETF'>HFXE</a>, <a href='https://seekingalpha.com/symbol/DEUR' title='VelocityShares Daily 4X Long USD vs. EUR ETN'>DEUR</a>, <a href='https://seekingalpha.com/symbol/EDOM' title='WisdomTree Europe Domestic Economy ETF'>EDOM</a>, <a href='https://seekingalpha.com/symbol/FLEE' title='Franklin FTSE Europe ETF'>FLEE</a>, <a href='https://seekingalpha.com/symbol/RFEU' title='First Trust RiverFront Dynamic Europe ETF'>RFEU</a>, <a href='https://seekingalpha.com/symbol/UEUR' title='VelocityShares Daily 4X Long EUR vs. USD ETN'>UEUR</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3337616\" data-linked=\"Dovish is the verdict (for now) on ECB\" data-tweet=\"$FXE $VGK $EUO - Dovish is the verdict (for now) on ECB https://seekingalpha.com/news/3337616-dovish-is-verdict-for-now-on-ecb?source=tweet\" data-url=\"https://seekingalpha.com/news/3337616-dovish-is-verdict-for-now-on-ecb\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337613\" data-ts=\"1520520639\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337613-cnbc-amazon-owes-22b-in-future-payments-related-to-whole-foods\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CNBC: Amazon owes $22B in future payments related to Whole Foods</a></h4><ul><li>        Amazon&rsquo;s (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) annual report includes a footnote revealing the company has <a href=\"https://www.cnbc.com/2018/03/07/amazon-purchase-obligations-to-unfi-show-confidence-whole-foods.html\" target=\"_blank\">$22B in additional commitments</a> related to its Whole Foods acquisition. The obligation lasts until 2025.</li><li>               The &ldquo;unconditional purchase obligations&rdquo; note includes $24.2B in future payment agreements for 2017. Amazon had $1.6B in obligations before the acquisition and never went above $2B.&nbsp;</li><li>               The money will go towards future food purchases, which experts say shows Amazon&rsquo;s commitment to growing the business, though the tactic isn&rsquo;t typical for grocery retailers.&nbsp;</li><li>               Amazon acquired Whole Foods last year for $13B.&nbsp;</li><li>               Amazon shares are&nbsp;<font color='green'>up 0.6%</font>&nbsp;to $1,554.27.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3337388-reuters-amazon-meeting-plan-direct-move-brazil-market\" target=\"_blank\">Reuters: Amazon meeting to plan direct move into Brazil market</a> (March 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3337613\" data-linked=\"CNBC: Amazon owes $22B in future payments related to Whole Foods\" data-tweet=\"$AMZN - CNBC: Amazon owes $22B in future payments related to Whole Foods https://seekingalpha.com/news/3337613-cnbc-amazon-owes-22b-in-future-payments-related-to-whole-foods?source=tweet\" data-url=\"https://seekingalpha.com/news/3337613-cnbc-amazon-owes-22b-in-future-payments-related-to-whole-foods\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>80&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337611\" data-ts=\"1520520336\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NEON\" target=\"_blank\">NEON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337611-neonode-misses-0_01-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Neonode misses by $0.01, beats on revenue</a></h4><ul><li>Neonode (NASDAQ:<a href='https://seekingalpha.com/symbol/NEON' title='Neonode, Inc.'>NEON</a>): FY EPS of -$0.09 <font color='red'>misses by $0.01</font>.</li><li>Revenue of $10.2M (-0.1% Y/Y) <font color='green'>beats by $0.46M</font>.</li><li>Shares <font color='green'>+4%</font>.</li><li><a href='https://seekingalpha.com/pr/17096808-neonode-reports-fourth-quarter-year-ended-december-31-2017-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3337611\" data-linked=\"Neonode misses by $0.01, beats on revenue\" data-tweet=\"$NEON - Neonode misses by $0.01, beats on revenue https://seekingalpha.com/news/3337611-neonode-misses-0_01-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3337611-neonode-misses-0_01-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:45 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337608\" data-ts=\"1520520168\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BTAI\" target=\"_blank\">BTAI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337608-bioxcel-therapeutics-prices-ipo-11\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioXcel Therapeutics prices IPO at $11</a></h4><ul><li>BioXcel Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/BTAI' title='BioXcel Therapeutics'>BTAI</a>) <a href=\"https://seekingalpha.com/pr/17096512-bioxcel-therapeutics-announces-pricing-initial-public-offering\" target=\"_blank\">prices </a>its IPO of ~5.45M shares of common stock at $11. Trading kicks off today.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3330633-bioxcel-therapeutics-deck-ipo\" target=\"_blank\">BioXcel Therapeutics on deck for IPO</a> (Feb. 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3337608\" data-linked=\"BioXcel Therapeutics prices IPO at $11\" data-tweet=\"$BTAI - BioXcel Therapeutics prices IPO at $11 https://seekingalpha.com/news/3337608-bioxcel-therapeutics-prices-ipo-11?source=tweet\" data-url=\"https://seekingalpha.com/news/3337608-bioxcel-therapeutics-prices-ipo-11\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337598\" data-ts=\"1520519401\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MU\" target=\"_blank\">MU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337598-micronplus-1_4-on-analyst-upgrade-to-20-upside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Micron +1.4% on analyst upgrade to 20% upside</a></h4><ul><li>        KeyBanc maintains an Overweight rating and raises its Micron (NASDAQ:<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology Inc.'>MU</a>) target from $53 to $65, a 20% upside to yesterday&rsquo;s close.</li><li>                  Latest analyst <a href=\"https://markets.ft.com/data/equities/tearsheet/forecasts?s=MU:NSQ\" target=\"_blank\">recommendations</a>: 10 Buy, 16 Outperform, and 3 Hold.    </li><li>               Median price target: $60. &nbsp;&nbsp;</li><li>               Micron shares are&nbsp;<font color='green'>up 1.4%</font>&nbsp;to $54.71 with a 52-week range of $24.81 to $55.&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3337598\" data-linked=\"Micron +1.4% on analyst upgrade to 20% upside\" data-tweet=\"$MU - Micron +1.4% on analyst upgrade to 20% upside https://seekingalpha.com/news/3337598-micronplus-1_4-on-analyst-upgrade-to-20-upside?source=tweet\" data-url=\"https://seekingalpha.com/news/3337598-micronplus-1_4-on-analyst-upgrade-to-20-upside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>187&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337596\" data-ts=\"1520519140\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HLTH\" target=\"_blank\">HLTH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337596-nobilis-health-q4-revenues-down-15-updates-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nobilis Health Q4 revenues down 15%; updates guidance</a></h4><ul><li>Nobilis Health (<a href='https://seekingalpha.com/symbol/HLTH' title='Nobilis Health Corp.'>HLTH</a>) <a href=\"https://seekingalpha.com/pr/17096122-nobilis-health-reports-fourth-quarter-full-year-2017-financial-results\" target=\"_blank\">Q4 results</a>: Revenues: $86.8M (-14.8%); Operating Income: $16.8M (-19.2%); Net Income: $3.6M (-61.7%); EPS: $0.05 (-58.3%); Quick Assets: $22.5M (-8.5%); CF Ops: $26.4M.</li><li><strong>2018 Guidance</strong>: Revenue: $345M - 355M; Adjusted EBITDA: $57M - 62M.</li><li>Shares are down&nbsp;<font color='red'>7%</font>&nbsp;premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3337596\" data-linked=\"Nobilis Health Q4 revenues down 15%; updates guidance\" data-tweet=\"$HLTH - Nobilis Health Q4 revenues down 15%; updates guidance https://seekingalpha.com/news/3337596-nobilis-health-q4-revenues-down-15-updates-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3337596-nobilis-health-q4-revenues-down-15-updates-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:25 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337597\" data-ts=\"1520519135\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEUM\" target=\"_blank\">TEUM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337597-pareteumplus-4_6-on-mvno-deal-to-enter-mexico\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pareteum +4.6% on MVNO deal to enter Mexico</a></h4><ul>   <li>Pareteum (NYSEMKT:<a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a>) has <font color='green'>picked up 4.6%</font> premarket after an MVNO deal that will see it <a href=\"https://seekingalpha.com/pr/17096434-pareteum-enters-mexican-market-5-year-4_5-million-mvno-agreement\" target=\"_blank\">entering the Mexican market</a>.</li>    <li>The company signed a five-year deal to provide its global cloud services to enable roaming, airtime, voice and SMS to a mobile virtual network operator.</li>    <li>The customer is a joint venture between an established social entrepreneur organization and a social capital business that focuses on financial inclusion for remote and economically disadvantaged regions.</li>    <li>Pareteum will be paid monthly for each subscriber on the platform and additionally for connectivity services; the deal is expected to generate $2.7M over 36 months in contractual backlog.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3337597\" data-linked=\"Pareteum +4.6% on MVNO deal to enter Mexico\" data-tweet=\"$TEUM - Pareteum +4.6% on MVNO deal to enter Mexico https://seekingalpha.com/news/3337597-pareteumplus-4_6-on-mvno-deal-to-enter-mexico?source=tweet\" data-url=\"https://seekingalpha.com/news/3337597-pareteumplus-4_6-on-mvno-deal-to-enter-mexico\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:25 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3337595\" data-ts=\"1520518890\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDRX\" target=\"_blank\">MDRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3337595-allscripts-says-singapore-business-ok-shares-up-2-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Allscripts says Singapore business OK; shares up 2% premarket</a></h4><ul><li>Allscripts (NASDAQ:<a href='https://seekingalpha.com/symbol/MDRX' title='Allscripts Healthcare Solutions, Inc.'>MDRX</a>), up&nbsp;<font color='green'>2%&nbsp;</font>premarket on light volume, is poised to recapture at least a portion of yesterday's&nbsp;<font color='red'>4%</font>&nbsp;selloff stoked by reports that some of its business in Singapore could be at risk after the Singapore Ministry of Health and Integrated Information Systems decided to go with two electronic medical record &#40;EMR&#41; vendors instead of one.</li><li>The company says the decision <a href=\"https://www.sec.gov/Archives/edgar/data/1124804/000119312518073936/d549277d8k.htm\" target=\"_blank\">will not impact</a> its current <a href=\"https://www.allscripts.com/market-solutions/hospitals-health-systems/electronic-health-records\" target=\"_blank\">Sunrise </a>client base there, representing ~54% of the public and 70% of the private hospital beds there. It also says it plans to implement Sunrise at the 1,400-bed SengKang General and Community Hospital system later this year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3337595\" data-linked=\"Allscripts says Singapore business OK; shares up 2% premarket\" data-tweet=\"$MDRX - Allscripts says Singapore business OK; shares up 2% premarket https://seekingalpha.com/news/3337595-allscripts-says-singapore-business-ok-shares-up-2-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3337595-allscripts-says-singapore-business-ok-shares-up-2-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM </div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}